WO2010039474A1 - Prodrugs of oxazolidinone cetp inhibitors - Google Patents

Prodrugs of oxazolidinone cetp inhibitors Download PDF

Info

Publication number
WO2010039474A1
WO2010039474A1 PCT/US2009/057657 US2009057657W WO2010039474A1 WO 2010039474 A1 WO2010039474 A1 WO 2010039474A1 US 2009057657 W US2009057657 W US 2009057657W WO 2010039474 A1 WO2010039474 A1 WO 2010039474A1
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
phenyl
independently selected
alkyl
mmol
Prior art date
Application number
PCT/US2009/057657
Other languages
French (fr)
Inventor
Sander G. Mills
Amjad Ali
Cameron Smith
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Priority to EP09818237.1A priority Critical patent/EP2348859B1/en
Priority to US13/121,972 priority patent/US8354454B2/en
Publication of WO2010039474A1 publication Critical patent/WO2010039474A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/20Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C219/22Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/26Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C219/28Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C329/00Thiocarbonic acids; Halides, esters or anhydrides thereof
    • C07C329/02Monothiocarbonic acids; Derivatives thereof
    • C07C329/04Esters of monothiocarbonic acids
    • C07C329/06Esters of monothiocarbonic acids having sulfur atoms of thiocarbonic groups bound to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/091Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/093Polyol derivatives esterified at least twice by phosphoric acid groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/094Esters of phosphoric acids with arylalkanols
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Definitions

  • This invention relates to prodrugs of oxazolidinone compounds which are CETP inhibitors.
  • CHD coronary heart disease
  • stroke and peripheral vascular disease represent a truly enormous burden to the health care systems of the industrialized world.
  • CHD coronary heart disease
  • CHD stroke and peripheral vascular disease
  • CETP cholesteryl ester transfer protein
  • CETP inhibitors which are widely used to help control cholesterol, are effective in reducing LDL-cholesterol (the "bad cholesterol") in patients, and are relatively less effective in raising HDL-cholesterol ("the good cholesterol").
  • CETP inhibitors are effective in raising HDL-cholesterol and may also reduce LDL-cholesterol.
  • CETP inhibitors therefore represent a potential new tool for controlling lipids and for treating or reducing CHD and atherosclerosis in the general population, either alone or in combination with a statin.
  • a combination of a CETP inhibitor and a statin may be especially advantageous in controlling lipids by raising HDL-C and reducing LDL-C.
  • Pfizer's torcetrapib is the only CETP inhibitor that has so far been tested in a large-scale clinical trial.
  • the trial (named ILLUMINATE) was stopped before its scheduled completion date, because the patients being treated with torcetrapib and atorvastatin in combination had a higher incidence of mortality than the control group, which was being treated only with atorvastatin.
  • Data generated after the termination of the ILLUMINATE trial using animal studies and further data analysis suggest that the higher incidence of mortality in the patient group treated with torcetrapib may have been due to off-target effects of the molecule rather than the mechanism of action.
  • Studies of other CETP inhibitors are therefore expected to occur, and new compounds are still being investigated.
  • Studies of two CETP inhibitors, dalcetrapib and anacetrapib are starting or are in progress.
  • CETP inhibitors are generally lipophilic, having poor solubility in water and in aqueous bodily fluids.
  • Oral formulations of the poorly soluble CETP inhibitors using conventional tablet formulations have limited aqueous solubility and generally exhibit a "food effect," whereby the amount of drug that is absorbed varies, depending on whether the patient
  • Liquid formulations of the oxazolidinone compounds in surfactants (WO2007/067593) and solid formulations of the oxazolidinone compounds in water soluble polymers (WO2007/092642) have been developed that provide improved solubility and bioavailability compared with conventional formulations of the drugs.
  • This application discloses an alternative approach to improving the oral availability of the drugs.
  • Prodrugs are disclosed which are easy to administer and which are converted to the active drug in vivo.
  • the prodrugs of the oxazolidinone compounds that are described in this application, the oxazolidinone ring is formed by a cyclization reaction which forms the active drug after administration to a patient.
  • a somewhat analogous approach has been disclosed in which a 5-membered heterocycle is produced as a by-product of a coupling reaction: W.S. Saari et al, J Med, Chem., 1990, 33, pp. 97-101.
  • the compound of Formula I is a prodrug which readily converts to the compound having Formula II when it is administered to a patient.
  • the prodrug is most often administered orally, though other routes of administration may also be used.
  • the prodrug converts to the active drug during or after administration, generally after administration.
  • the compound of formula I is converted to the active oxazolidinone compound of formula II by a cyclization reaction or reactions in which the N and carbonyl are joined together to form the 5-membered oxazolidinone ring of the compound of formula II.
  • Rl is H or Ci_4alkyl, which is optionally substituted with 1-5 F groups;
  • Each R.2 is independently selected from the group consisting of halogen, -CN, Ci-4alkyl, and -OCi-4alkyl, wherein Ci-4alkyl and -OCi_4alkyl are optionally substituted with
  • R4 and R5 are each independently selected from the group consisting of halogen,
  • R3 is selected from H, halogen, Ci ⁇ alkyl, and -OCi-4alkyl, wherein Ci ⁇ alkyl and -OCi-4alkyl are optionally substituted with 1-5 halogens; a and b are integers which are each independently selected from from 0-4; and c is an integer from 0-2.
  • X is a leaving group which is displaced by the N during the cyclization reaction in which I is converted to II.
  • X has the structure -OZ or -SZ, wherein: Z is selected from
  • _0P( O)(OR 7 ) 2 , and -P( ⁇ O)(OR 7 ) 2 , wherein phenyl is optionally substituted with 1-3 groups independently selected from halogen, -C(-O)OR 7 , and Ci ⁇ C 3 alkyl optionally substituted with 1-3 halogens; and
  • phenyl is optionally substituted with 1-3 groups independently selected from halogen; Ci-C 5 alky ⁇ ; -OCs-C 5 alkyl; -C( ⁇ O)OR 7 ; and C 5 - C 7 cycloalkyl optionally substituted with 1-2 groups independently selected from halogen, Q- C 3 alkyl > -OCi-C 3 alkyl, CF 3 , and -OCF 3 ; wherein C ⁇ -C 5 alkyl and -OC r C 5 alkyl are optionally substituted with 1-5 F and are optionally substituted with 1-2 groups independently selected from -C(O)OR 7 , -N(R 7 ) 2 , -OP(-O)(OR 7 ) 2j and -P(-O)(OR 7 ) 2 ;
  • R 6 is selected from H and C1-C5 alkyl which is optionally substituted with 1-5 halogens and is optionally substituted with 1-2 phenyl groups wherein phenyl is optionally substituted with 1-3 groups independently selected from halogen, C 1 -C 3 alkyl, -OCj-C 3 alkyl, CF 3 , and -OCF 3 ; and
  • R 7 is selected from H and C] -C 3 alkyl optionally substituted with 1-3 F.
  • Rl is H or Cl _3 alkyl, optionally substituted with 1-5 F.
  • Rl in preferred embodiments is Cl -2 alkyl, optionally substituted with 1-3 F.
  • Rl is Ci- 2 alkyl.
  • Rl is CH3.
  • each R2 is independently selected from -CN, F, Ci-3alkyl optionally substituted with 1-5 F, and -OCi .3 alkyl optionally substituted with 1-5 F.
  • each R ⁇ is independently selected from -CN, F, Ci-3alkyl optionally substituted with 1-5 F, and -0Ci-2alkyl optionally substituted with 1-5F.
  • each R2 is independently selected from -CN, Ci-3alkyl, CF3, -OCH3, -0CF3, and F.
  • each R2 is independently selected from -CN, CH3 and CF3. In other preferred embodiments, each R2 is CH3 or CF3, And in other preferred embodiments, R2 is CF 3,
  • R ⁇ and R5 are each independently selected from F, Ci_3alkyl optionally substituted with 1-5 F, and -0Cl-3aIkyl optionally substituted with 1-5 F.
  • R4 and R5 are each independently selected from F, Ci -3 alkyl optionally substituted with 1-5 F, and -0Ci-2alkyl optionally substituted with 1-5F.
  • R4 and R5 are each independently selected from Cl -3 alkyl, CF3, -OCH3, -OCF3, and F.
  • each R.4 is independently selected from Ci-3alkyl, CF3, -OCH3, -0CF3 > and F.
  • each R4 is independently selected from Ci-3alkyl, CF3, -OCH3, and F.
  • each R4 is independently selected from Ci-3alkyl 5 -OCH3, and F.
  • R ⁇ is Cl-3alkyl, -0Cl-3alkyl , or F, wherein Ci ⁇ 3alkyl and OCi-3alkyl are optionally substituted with 1-5 F.
  • R3 is CH3, CF3 or F. In other preferred embodiments, R ⁇ is CF3.
  • a is 1 or 2. In other preferred embodiments, a is 2. In preferred embodiments, b is an integer from 1-3. In other preferred embodiments, b is 2 or 3. In other preferred embodiments, b is 3.
  • c is 0 or 1. In other preferred embodiments, c is 0.
  • Z is selected from
  • R6 is selected from H and Ci-C2alkyl which is optionally substituted with one phenyl group, said phenyl being optionally substituted with 1-3 groups independently selected from halogen, CH3, CF3, -OCH3, and -OCF3.
  • R 7 is selected from H and C 1 -C 3 alkyl optionally substituted with 1-3 F.
  • X is selected from -SCi-C3alkyI and -OZ. In some embodiments, X is selected from -SCi -C2alkyl an d -OZ. In some embodiments, X is -SCi-C2aIkyl. In some embodiments, X is -OZ.
  • Z is selected from
  • Z is selected from the group consisting of: (a) -(CH2CH2 ⁇ -) n Ci-C3alkyl, wherein C]-C3alkyl is optionally substituted with
  • R ⁇ is selected from H, Ci ⁇ C2alkyI, and -CH2phenyI.
  • R 7 is selected from H and C] -C2alkyl.
  • a particularly preferred embodiment of this invention is directed to prodrugs for making the compound having formula III, including pharmaceutically acceptable salts thereof:
  • the prodrug that is converted to Compound III when it is administered to a patient has the formula IV, shown below, where X is as defined previously.
  • the prodrugs of Formula I and IV described above chemically eliminate the oxazolidinone-based drug under buffered conditions at a pH in the range of 7.0-8.0, and preferably at about 7.5, and at a temperature of about 37 0 C (in the range of about 36-38 ° C).
  • the compounds and the formulations of the compounds are useful in treating diseases which are characterized by low-HDL and/or high-LDL, or which can be treated or ameliorated by raising HDL and/or reducing LDL such as hypercholesterolemia, hyperlipidemia, and atherosclerosis. Furthermore, administration of the compounds and formulations described herein does not cause an increase in blood pressure as was observed for torcetrapib.
  • Doses of the prodrug in humans that will be therapeutically effective in raising HDL and lowering LDL are the amounts that are equivalent after cyclization to active drug in an amount in the range of 20mg to 200mg, such as for example 20mg, 25 mg, 30 mg, 40mg, 50mg, 60mg, 70 mg, 80 mg, 90 mg, 100 mg, l lOmg, 120mg, 130mg ? 140mg, 150mg, 160mg, 180mg and 200mg, administered once or twice a day, but preferably once a day.
  • a preferred dose will provide 100 mg of active drug and will be administered once a day.
  • the prodrugs provide improved bioavailability compared with conventional formulations of the active drug. Furthermore, conventional formulations comprising the CETP inhibitors that are made from the prodrugs herein exhibit a "food effect," which results in differences in the amount and rate of absorption into the body depending on when the patient was last fed, how soon the patient eats after oral administration of the drug, and whether the patient takes the drug before a meal, with a meal, or after a meal.
  • the prodrug formulations disclosed herein should exhibit a reduced food effect compared with conventional formulatons because they cyclize to the active drag after the prodrug has passed into the small intestine, which is the site of absorption.
  • Step B /erf-Butyl 2-f(fer?-butoxycarbon ⁇ l)aminol-3-(4-hvdroxy-3-methoxy ⁇ henyl) ⁇ ropanoate
  • Step A 4-(2-Bromoethyi)phenyl acetate
  • Step B 4-f2- ⁇ [Bis(benzylox ⁇ ) ⁇ hosphoryl]oxy ⁇ ethyl)phenyl acetate
  • Step C Dibenzyl 2-(4-hydroxyphenyl)ethyl phosphate
  • Step B 4-(2-Hvdroxyethoxy)-2-methoxv ⁇ henol
  • Step C 4-(2-Hydroxyethoxy)-2-methoxyphenyl acetate
  • Step D 4-(2-Bromoethoxy)-2-methoxyphenyl acetate
  • Step E 4-(2- ⁇
  • Step F Dibenzyl 2-(4-hydroxy-3-methoxyphenoxy)eth ⁇ l phosphate
  • Step B Methyl 2-(acetyloxy)-5 -iodo-3-methylbenzoate To a stirred suspension of 2-hydroxy-5 -iodo-3-methylbenzoate (1.24 g, 4.25 mmol) in neat acetic anhydride (1.803 mL, 19.10 mmol) was added a 3 drops of concentrated sulfuric acid (0.226 mL, 4.25 mmol). The resultant orange solution was stirred at room temperature overnight. The solution was diluted with 3% aqueous NaHCO 3 (13 mL) and extracted with CHCl 3 (3 x 30 mL).
  • Step C Methyl 2-(acetyIoxy)-5-(3-hydroxyprop-l-yn-l-yl)-3-rnethy.lbenzpate
  • Triethylamine (0.943 mL, 6.76 mmol) and bis(triphenylphosphine)palladium( ⁇ I) chloride (0.092 g, 0.132 mmol) were added to a mixture of methyl 2-(acetyloxy)-5-iodo-3- methylbenzoate (1.0 g 5 2.99 mmol) and propargyl alcohol (0.161 mL, 2.69 mmol) in THF (20 mL) at room temperature, and then copper (I) iodide (0.053 g, 0.278 mmol) was added.
  • Step D Methyl 2-(acetyloxy)-5-[(l ⁇ -3-hydroxyprop-l-en-l-yI]-3-methylbenzoate
  • a suspension of methyl 2 ⁇ (acet ⁇ Ioxy)-5-(3-hydroxyprop-l-yn-l-yl)-3- methylbenzoate (0.417 g, 1.590 mmol) and palladium on carbon (170 mg, 1.597 mmol) in EtOAc (20 mL) was stirred at room temperature under a balloon atmosphere of H 2 for 3 days.
  • the reaction mixture was filtered through a plug of Celite and washed through with EtOAc (3x30 mL).
  • the filtrate was concentrated in vacuo to give the crude product. This was purified by flash chromatography (Si, 0-20% EtOAc in hexanes over 40 min) to afford methyl 2-
  • Step , F Methyl 2-(acetyloxy)-5-(3- ⁇
  • Dibenzyl N,N-diisopro ⁇ yl ⁇ hosphoramidite (0.252 mL, 0.751 mmol) was added to a stirred solution of lH-tetrazole (3 wt% in CH 3 CN) (4.40 mL, 1.502 mmol) and methyl 2- (acet ⁇ loxy)-5-(3-hydro ⁇ ypropy!-3-methylbenzoate (100 mg, 0.376 mmol) in dry CH 2 Cl 2 (4.50 mL) at 25 0 C under N 2 . The reaction was stirred for 2 h at 25 0 C.
  • Step G Methyl , 5 -(3 - ⁇ [bis(benzyloxy)phosphoryl] oxy ⁇ propyl)-2-hydroxy-3 -methylbenzoate K 2 CO 3 (108 mg, 0.784 mmol) was added to a stirred solution of methyl 2-
  • Step B 4 ⁇ Hydroxy-2-isoprop ⁇ xybenzaldehyde
  • Step A 2-Phenyl-5-[2-(tetrahvdro-2/f-pyran-2-yloxy)ethoxy]-l ,3-dioxane
  • Step B 2-[2-(Tetrahydro-2//- ⁇ yran-2-yloxy)ethoxy]propane-K3-diol
  • Step C Tetrabenzyl 2-
  • Dibenzyl N,N-diiso ⁇ ropyl ⁇ hos ⁇ horamidite (1.43 mL, 4.26 mrnol) was added to a stirred solution of ltf-tetrazole (0.45 M in CH 3 CN) (18.9 mL, 8.52 mmol) and 2-[2-(tetrahydro ⁇ 2H-pyran-2-yloxy)ethoxy] propane- 1, 3 -diol (312.6 mg, 1.419 mmol) in dry CH 2 Cl 2 (17.0 mL) at 25 0 C under N 2 .
  • Step D Tetrabenzyl 2-(2-hydroxyethoxy)pro ⁇ ane-l,3-diyl bis(phosphate)
  • Step A 4-(Benzyloxy)-2-isopropoxybenzaldehydc K 2 CO 3 (6.14 g, 44.4 mmol) and 2-iodopropane (1.28 mL, 12.76 mmol) were added successively to a stirred solution of 4-benzyloxy-2-hydroxybenzaldehyde (2.33 g, 10.21 mmol) in dry DMF (12.8 mL) at 25 0 C under N 2 . The reaction was heated at 50 0 C overnight.
  • Triethylamine (4.27 mL, 30.7 mmol) was added to a solution of 4-(benzyloxy)-2- isopropoxyphenol (2.64 g, 10.22 mmol) in dry CH 2 Cl 2 (40.9 mL) and the resulting solution was cooled to 0 0 C.
  • Benzoyl chloride (1.54 mL, 13.29 mmol) was added dropwise and the reaction was stirred at 25 0 C overnight.
  • the reaction mixture was washed with water (50 mL).
  • the aqueous layer was separated and extracted with CH 2 Cl 2 (2 x 20 mL).
  • the combined organic layers were dried (MgSO ⁇ and concentrated in vacuo to give the crude product.
  • Step E 2-Isopro ⁇ oxy-4-[(2-phenyl-l,3-dioxan-5-yl)oxy]phenyl benzoate Diethyl azodicarboxylate (173 ⁇ L, 1.102 mmol) was added to a stirred solution of
  • Step F 4-r2-Hydroxy-l-(hydroxymethyl)ethoxy]-2-isopropo ⁇ yphenyl benzoate A suspension of 10% palladium on carbon (38.9 mg, 0.037 mmol) in a solution of
  • Step G 4-[2- ⁇ [Bis(benzyloxy)phosphoryl)oxy ⁇ -l- ( / ⁇ [bis(benzyl ⁇ xy)phosphoryl]oxy ⁇ methyl)ethoxy1-2-iso ⁇ ropoxyphenyl benzoate
  • Step H Tetrabenzyl 2-(4-hydroxy-3-isopropoxyphenoxy ' )propane-l,3-diylbis(phosphate)
  • Step B ( 1 R,2S)- l,-[3 ,5-Bis(trifluoromethyl)phenyl] - 1 - ⁇ [(2,6-dimethoxyphenoxy)carbonyl] oxy ⁇ - N- ⁇ r4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]methy3 ⁇ ⁇ ro ⁇ an-2- arninium chloride
  • Step B 2-Methoxy-4-(2- ⁇ [(4-methylphenyl)sulfonyl1oxvlethyl)p,henyl acetate
  • Step C 4-f2-Iodoethyl)-2-methoxyphenyl acetate
  • Step D 4-(2- ⁇ [Bis(benzvloxv)phosphoryI1oxy ⁇ ethyl)-2-methoxyphenyl acetate
  • Silver dibenzylphosphate (0.950 g, 2.47 mraol) was added to a solution of 4-(2- iodoethyl)-2-methoxyphenyl acetate (0.79 g, 2.47 mmol) in dry toluene (20 mL) and the mixture was heated at reflux overnight.
  • the precipitated formed was removed by filtration through a plug of Celite and washed through with toluene.
  • the filtrate was concentrated in vacuo to give the crude product.
  • Step E Dibenzyl 2-(4-hydroxy-3-methoxyphenyl)ethyl phosphate
  • Step F 4-f2- ⁇ [Bis(benzyloxy)phosphoryl]oxyiethyl)-2-methoxyphenyl (IRjLS)-I-B 5- bis(trifluoromethyl)phenyl] -2-(f ferf -butoxycarbonyl) ⁇ [4'-fluoro-5 '-isopropyl-2'-methoxy-4- (trifluoromethyl)biphenyl-2-yl)methyl ⁇ amino)propy 1 carbonate
  • Step G fli?,2 ⁇ -l-[3,5-Bis(trifluoromethvl)phenyll-2-f(/e ⁇ -butoxycarbonylHr4'-fluoro-5'- iso ⁇ ropyl-2'-methoxy : 4-(trifluoromethyl)biphenyl-2-yl]methyl ⁇ amino)propyl 2-methoxy-4-[2- (phos ⁇ hon ⁇ oxy)ethyl] phenyl carbonate
  • reaction mixture was filtered through a plug of Celite and the filtrate was concentrated in vacuo to afford (17?,25)- l-[3 5 5-bis(trifluoromethyl)phenyl]-2-((tert-butoxycarbonyl) ⁇ [4'-fluoro-5'-isopropyl-2'-methoxy- 4-(trifluoromethyl)biphenyl-2-yl]methyl ⁇ amino)propyl 2-methoxy-4-[2-
  • Step H (li?,2y)-l-l ' 3,5-Bis( ' trifluoromethyl)phenvil ⁇ N- ⁇ [ ' 4 ⁇ -fluoro-5'-isopropyl-2'-methoxv-4- (trifluoromethyl)biphenyl-2-yl]methyU - 1 -f( ⁇ 2-methoxy-4-f2- (phosphonooxy)eth ⁇ I]phenoxy ⁇ carbonyl)oxy]propan-2-aminium chloride
  • Step A te ⁇ t-Butyl(4-hydroxy-3-rnethoxybenzyl)carbamate
  • Step B f 1 R2S)- 1 - [3 ,5 -B is(trifluoromethyl)pheny 1] -2 -((f erfrbutoxycarbony Q ⁇
  • Step C ( 1 R2S)- 1 -( I [4-(Ammoniomethyl V2-methoxyphenoxy3carbonyi > oxy)- 1 - [3 ,5- bis(trifluoromethyl)pherryl ⁇ -N- ⁇ [4' -fluoro-5 ' -isopropyl-2' -methoxy-4-(trifluoromethyl)biphenyl- 2-yl I methyl I propan-2-aminium dichloride
  • Step A (l J ff,2 i S f )-l-j " 3.5-Bisftrifluoromethyl)phenylV2-fferf-butoxvcarbonyl)(r4'-fluoro-5'- isopropyl-2'-methoxy-4-(trifluoromethyl)biphen ⁇ l-2-vl]methyl ⁇ amino)propyl chloromethyl carbonate
  • Step B ([Bi sf benzylox y) ⁇ ho sphoryll oxy) methylf IR 2S)-I- j " 3 ,5-bis(trifluoromethyl)phenvI 1 -2- f ⁇ rf-butoxycarbonyl) ⁇ f4'-fluoro-5 ?
  • Step C riJ?,2 1 y)-l-[3,5-Bis ⁇ rifluoromethvnphenyl]-2-(fert-butoxycarbonyl) ⁇ f4'-fluoro-5'- isopropyl-2 ' -methoxy-4-(trifluoromethyl)biphenyl ⁇ 2-yl]methyl ⁇ amino)prppyl (phosphonooxy)meth ⁇ l carbonate
  • Step D (IRSS)-I- [3 ,5 -Bisf trifluoromethyDphenvl] -JV- f [4 ' -fluoro-5 ' -isopropyl-2 ' -methoxy-4- (trifluoromethyl)biphenyl-2-yl] methyl ⁇ - 1 , 1 -dihydroxy-S-oxo- ⁇ A , 6-trioxa- 1 -phosphanonan-8- aminium- 1 -oxide chloride
  • Step A Benzyl (6R J ) S f )-643,5-bis(trifluoromethvl)phenvl]-8- ⁇ [4'-fluoro-5'-isopropyl-2 > - methoxy-4-(trifluor ⁇ methyl ⁇ biphenyl-2-yl]methyl ⁇ -7,1 1,11 -trimethyl-4,9-dioxo-3,5 J 0-trioxa-8- azadodecati- 1 -oate Pyridine (0.037 mL, 0.46 mmol) was added dropwise to a stirred solution of benzyl glycolate (76 mg, 0.46 mmol) and triphosgene (42 mg, 0.14 mmol) in dry CH 2 Cl 2 (4.0 mL) at 0 0 C under N 2 . The reaction was stirred at 25 0 C for 1.5 h. A solution of tert-butyl
  • Step B (6 ⁇ J5)-6-[3 ⁇ 5-Bis(trifiuoromethvnphenyl]-8- ⁇ [4'-fluoro-5'-isopropyl-2'-methoxy-4- (trifluoromethyl)biphenyl-2-yl]methyl ⁇ -7, 11,11 -trirnehtyl-4,9-dioxo-3,5, 10-trioxa-8-azadodecan- 1 -oic acid
  • Step C (1 &2S)- 1 - F3 , 5 ⁇ Bis(trifluoromethy Hphenyl] - 1 - ⁇ [f carboxymetho ⁇ y)carbony lioxy I -N- i f 4 ' - flupro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]rnethyl ⁇ propan-2-aminium chloride
  • Step B (IR2S)- 1 -r3,5-Bisrtrifiuoromethyl)phenyll-2-((fe ⁇ -butoxycarbonyl) ⁇ f4 ! -fluoro-5'- isopropyl-2'-methox ⁇ -4-(trifluoromethyl)biphenyl-2-yl]methyl ⁇ amino)propyl 2-hydrox ⁇ - 1 - (hydroxymethyDethyl carbonate
  • Step C 2- ⁇ [Bis(benzyloxy)phosphoryl] oxy I - 1 -( ⁇ [bis(benzyloxy)phosphoryl] oxy ⁇ methyl)ethyl fli?,2 ⁇ -l-f3,5-bisftrifluoromethvDphenyll-2-(( ' /erf-butoxvcarbonyl) ⁇ [4'-fluoro-5'-isopropyl-2'- methoxy-4-f trifluoromethyl)biphenyl-2-yl] methyl ⁇ amino)propyl carbonate
  • the reaction was stirred for 3 h at 25 0 C.
  • the reaction mixture was cooled to 0 0 C and a solution of 3- chloroperoxybenzoic acid (69.0 ⁇ L, 0.308 mmol) in dry CH 2 Cl 2 (1.43 mL) was added via cannula and the reaction was stirred at 0 0 C.
  • the reaction was diluted with EtOAc (25 mL) and washed with successive portions of saturated Na 2 SO 3 (20 mL) and saturated NaHCO 3 (20 mL), dried (Na 2 SO 4 ) and concentrated in vacuo to afford the crude product.
  • Step D (lj?,2y)-l-r3,5-Bis(trifluoromethvnphenvl1-2-((fe ⁇ -butoxvcarbonvl) ⁇ [4 1 -fluoro-5'- isopropyl-2'-methoxy-4-(trifluoromelhyl)bi ⁇ henyl-2-yl]me1Jhyl ⁇ amino)propyl 2-(phosphonooxy)- 1 -fYphosphonooxy)methyl ] ethyl carbonate A suspension of 10% palladium on carbon (6.0 mg, 5.65 ⁇ mol) in a solution of 2-
  • Step E (8 &95V 8-f3,5-Bis ⁇ rifluoromethyl)phenyl
  • the sodium salt of EXAMPLE 35 (20 mg, 0.025 mmol) was dissolved (sonicated to ensure dissolution) in 100 mM sodium phosphate buffer in D 2 O (pH 7.52, 2.2 mL) and heated at 37 0 C in an oil bath. 50 ⁇ L aliquots were removed periodically. An aliquot was taken at 3 minutes, then every 15 minutes until 135 minutes from the start, then every 30 minutes until 225 minutes from the start. Each aliquot was diluted with MeCN-d 3 (150 ⁇ L), and a 1 H NMR spectrum was acquired (128 scans at 25 0 C, with acquisition starting 3 minutes after the aliquot was taken from the reaction).
  • the t l/2 was determined by examining the spectra to find the point in time where the ratio of starting material (SM) and product was 1 :1, based on 2 independent resolved signals in the aromatic region. The t 1/2 was found to be 75-90 min. Liquid chromatography - mass spectrometry (LCMS) of the reaction mixture showed the oxazolidinone III to be the main product. A small amount of SM remained along with a compound having a minor NMR peak that may be attributed to the corresponding carbamate. A small amount (ca. 1%) of the monoethyl ester byproduct was also present as a contaminant from the BOC deprotection step.
  • LCMS liquid chromatography - mass spectrometry
  • Table 4 below provides half-life data for some of the compounds described above.
  • the methods for determining the half-lives were approximately the same as described above, with variations in procedure depending on such variables as solubility and reaction rates.
  • the half-life can thus be adjusted by a practitioner in the art by making structural changes in the Z group, thereby optimizing the rate of cyclization to maximize the amount of absorption and minimize the magnitude of the food effect.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The compounds of Formula I are prodrugs of CETP inhibitors having a central oxazolidinone ring. The compounds cyclize by the elimination of HX to form an oxazolidinone ring after administration to a patient.

Description

TITLE OF THE INVENTION
PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS
FIELD OF THE INVENTION This invention relates to prodrugs of oxazolidinone compounds which are CETP inhibitors.
BACKGROUND OF THE INVENTION
Atherosclerosis and its clinical consequences, coronary heart disease (CHD), stroke and peripheral vascular disease, represent a truly enormous burden to the health care systems of the industrialized world, In the United States alone, approximately 13 million patients have been diagnosed with CHD, and greater than one half million deaths are attributed to CHD each year. Further, this toll is expected to grow over the next quarter century as the average age of the population increases and as an epidemic in obesity and diabetes continues to grow. Inhibition of cholesteryl ester transfer protein (CETP) is a potential new approach to reducing the incidence of atherosclerosis. Statins, which are widely used to help control cholesterol, are effective in reducing LDL-cholesterol (the "bad cholesterol") in patients, and are relatively less effective in raising HDL-cholesterol ("the good cholesterol"). CETP inhibitors are effective in raising HDL-cholesterol and may also reduce LDL-cholesterol. CETP inhibitors therefore represent a potential new tool for controlling lipids and for treating or reducing CHD and atherosclerosis in the general population, either alone or in combination with a statin. A combination of a CETP inhibitor and a statin may be especially advantageous in controlling lipids by raising HDL-C and reducing LDL-C.
Pfizer's torcetrapib is the only CETP inhibitor that has so far been tested in a large-scale clinical trial. The trial (named ILLUMINATE) was stopped before its scheduled completion date, because the patients being treated with torcetrapib and atorvastatin in combination had a higher incidence of mortality than the control group, which was being treated only with atorvastatin. Data generated after the termination of the ILLUMINATE trial using animal studies and further data analysis suggest that the higher incidence of mortality in the patient group treated with torcetrapib may have been due to off-target effects of the molecule rather than the mechanism of action. Studies of other CETP inhibitors are therefore expected to occur, and new compounds are still being investigated. Studies of two CETP inhibitors, dalcetrapib and anacetrapib, are starting or are in progress.
CETP inhibitors are generally lipophilic, having poor solubility in water and in aqueous bodily fluids. Oral formulations of the poorly soluble CETP inhibitors using conventional tablet formulations have limited aqueous solubility and generally exhibit a "food effect," whereby the amount of drug that is absorbed varies, depending on whether the patient
- I - takes the drug with a meal or in a fasted state, Efforts have been made to develop formulations that have better bioavailability. A potent class of substituted oxazolidinones, imidazolidinones, and other similar 5-membered heterocycles (see WO 2006/014357 and WO 2006/014413) was recently disclosed. As was observed with other CETP inhibitors, the compounds have poor water solubility. A particularly active compound that is disclosed in these applications is anacetrapib, which is the oxazolidinone compound pictured herein as compound III. Liquid formulations of the oxazolidinone compounds in surfactants (WO2007/067593) and solid formulations of the oxazolidinone compounds in water soluble polymers (WO2007/092642) have been developed that provide improved solubility and bioavailability compared with conventional formulations of the drugs.
This application discloses an alternative approach to improving the oral availability of the drugs. Prodrugs are disclosed which are easy to administer and which are converted to the active drug in vivo. With the prodrugs of the oxazolidinone compounds that are described in this application, the oxazolidinone ring is formed by a cyclization reaction which forms the active drug after administration to a patient. A somewhat analogous approach has been disclosed in which a 5-membered heterocycle is produced as a by-product of a coupling reaction: W.S. Saari et al, J Med, Chem., 1990, 33, pp. 97-101.
SUMMARY OF THE INVENTION The present invention provides a prodrug having formula I:
Figure imgf000004_0001
The compound of Formula I is a prodrug which readily converts to the compound having Formula II when it is administered to a patient. The prodrug is most often administered orally, though other routes of administration may also be used. The prodrug converts to the active drug during or after administration, generally after administration. The compound of formula I is converted to the active oxazolidinone compound of formula II by a cyclization reaction or reactions in which the N and carbonyl are joined together to form the 5-membered oxazolidinone ring of the compound of formula II.
Figure imgf000005_0001
In the compounds having Formula I and Formula II:
Rl is H or Ci_4alkyl, which is optionally substituted with 1-5 F groups;
Each R.2 is independently selected from the group consisting of halogen, -CN, Ci-4alkyl, and -OCi-4alkyl, wherein Ci-4alkyl and -OCi_4alkyl are optionally substituted with
1-5 halogens; R4 and R5 are each independently selected from the group consisting of halogen,
Ci-4alkyl, and -OCi-4alkyl, wherein Ci-4alkyl and -OCi-4alkyl are optionally substituted with
1-5 halogens;
R3 is selected from H, halogen, Ci^alkyl, and -OCi-4alkyl, wherein Ci^alkyl and -OCi-4alkyl are optionally substituted with 1-5 halogens; a and b are integers which are each independently selected from from 0-4; and c is an integer from 0-2.
In the prodrug of Formula I, X is a leaving group which is displaced by the N during the cyclization reaction in which I is converted to II.
X has the structure -OZ or -SZ, wherein: Z is selected from
(a) Ci-Cs alkyl which optionally includes an -O- atom between 2 adjacent carbon atoms, wherein said C1-Cs alkyl is optionally substituted with 1-5 halogens and is optionally substituted with 1 -2 substituent groups independently selected from phenyl, -C(=O)OR6,
_0P(=O)(OR7)2, and -P(^O)(OR7)2, wherein phenyl is optionally substituted with 1-3 groups independently selected from halogen, -C(-O)OR7, and Ci~C3alkyl optionally substituted with 1-3 halogens; and
(b) phenyl, wherein phenyl is optionally substituted with 1-3 groups independently selected from halogen; Ci-C5alkyϊ; -OCs-C5alkyl; -C(^O)OR7; and C5- C7cycloalkyl optionally substituted with 1-2 groups independently selected from halogen, Q- C3alkyl> -OCi-C3alkyl, CF3, and -OCF3; wherein Cϊ-C5alkyl and -OCrC5alkyl are optionally substituted with 1-5 F and are optionally substituted with 1-2 groups independently selected from -C(O)OR7, -N(R7)2, -OP(-O)(OR7)2j and -P(-O)(OR7)2;
R6 is selected from H and C1-C5 alkyl which is optionally substituted with 1-5 halogens and is optionally substituted with 1-2 phenyl groups wherein phenyl is optionally substituted with 1-3 groups independently selected from halogen, C1-C3 alkyl, -OCj-C3 alkyl, CF3, and -OCF3; and
R7 is selected from H and C] -C3 alkyl optionally substituted with 1-3 F.
DETAILED DESCRIPTION OF THE INVENTION
In embodiments of the compounds of Formula I and II described above, Rl is H or Cl _3 alkyl, optionally substituted with 1-5 F. Rl in preferred embodiments is Cl -2 alkyl, optionally substituted with 1-3 F. In other preferred embodiments, Rl is Ci- 2 alkyl. In other preferred embodiments, Rl is CH3.
In embodiments of the compound of Formula I and II, each R2 is independently selected from -CN, F, Ci-3alkyl optionally substituted with 1-5 F, and -OCi .3 alkyl optionally substituted with 1-5 F. In other embodiments, each R^ is independently selected from -CN, F, Ci-3alkyl optionally substituted with 1-5 F, and -0Ci-2alkyl optionally substituted with 1-5F. In preferred embodiments, each R2 is independently selected from -CN, Ci-3alkyl, CF3, -OCH3, -0CF3, and F.
In other preferred embodiments, each R2 is independently selected from -CN, CH3 and CF3. In other preferred embodiments, each R2 is CH3 or CF3, And in other preferred embodiments, R2 is CF 3,
In embodiments of the compound of Formula I and II, R^ and R5 are each independently selected from F, Ci_3alkyl optionally substituted with 1-5 F, and -0Cl-3aIkyl optionally substituted with 1-5 F. In other embodiments, R4 and R5 are each independently selected from F, Ci -3 alkyl optionally substituted with 1-5 F, and -0Ci-2alkyl optionally substituted with 1-5F. In other embodiments, R4 and R5 are each independently selected from Cl -3 alkyl, CF3, -OCH3, -OCF3, and F. In preferred embodiments, each R.4 is independently selected from Ci-3alkyl, CF3, -OCH3, -0CF3> and F. In other preferred embodiments, each R4 is independently selected from Ci-3alkyl, CF3, -OCH3, and F. In other preferred embodiments, each R4 is independently selected from Ci-3alkyl5 -OCH3, and F.
In embodiments, Rβ is Cl-3alkyl, -0Cl-3alkyl , or F, wherein Ci~3alkyl and OCi-3alkyl are optionally substituted with 1-5 F.
In preferred embodiments, R3 is CH3, CF3 or F. In other preferred embodiments, R^ is CF3.
In preferred embodiments, a is 1 or 2. In other preferred embodiments, a is 2. In preferred embodiments, b is an integer from 1-3. In other preferred embodiments, b is 2 or 3. In other preferred embodiments, b is 3.
In preferred embodiments c is 0 or 1. In other preferred embodiments, c is 0.
In some embodiments, Z is selected from
(a) C1-Cj alkyl which optionally includes an -O- atom between 2 adjacent carbon atoms, wherein said C1-C5 alkyl is optionally substituted with 1-3 F and is optionally substituted with 1-2 substituent groups independently selected from phenyl,
Figure imgf000007_0001
and -P(=O)(OR7)2, wherein phenyl is optionally substituted with 1-3 groups independently selected from halogen, Ci-C3alkyl, CF3, and -C(K))OR?; and
(b) Phenyl, wherein phenyl is optionally substituted with 1-3 groups independently selected from halogen; Ci-Csalkyl; CF3; -OCj-Csalkyl; -OCF3; -C(O)OR7; and Cs-Cgcycloalkyl which is optionally substituted with 1-2 groups independently selected from halogen, CH3., and -OCH3; wherein Ci-Csalkyl and -0C]~C3alkyI are optionally substituted with 1-2 groups independently selected from -C(=0)0R7, -N(R^)2, -OP(=O)(OR7)2; and -P(=O)(OR7)2.
In some embodiments, R6 is selected from H and Ci-C2alkyl which is optionally substituted with one phenyl group, said phenyl being optionally substituted with 1-3 groups independently selected from halogen, CH3, CF3, -OCH3, and -OCF3.
In some embodiments, R7 is selected from H and C1-C3 alkyl optionally substituted with 1-3 F.
In some embodiments, X is selected from -SCi-C3alkyI and -OZ. In some embodiments, X is selected from -SCi -C2alkyl and -OZ. In some embodiments, X is -SCi-C2aIkyl. In some embodiments, X is -OZ.
In some embodiments, Z is selected from
(a) -(CH2CH2θ-)nCi-C3alkyl, where n is 0 or 1, and wherein Ci-C3alkyl is optionally substituted with 1-2 substituent groups independently selected from phenyl,
Figure imgf000008_0001
wherein phenyl is optionally substituted with one group ~C(=O)OR7; and
(b) phenyl, which is optionally substituted with 1-3 substituents independently selected from C1-C4 alkyl, -OCi-C3aIkyl, -C(=O)OR7, and cyclohexyl, wherein C1-C4 alkyl and -0Cj-C3alkyl are optionally substituted with 1-2 groups independently selected from -N(R7)2, -C(O)OR?, and -OP(=O)(OR7)2-
In some embodiments, Z is selected from the group consisting of: (a) -(CH2CH2θ-)nCi-C3alkyl, wherein C]-C3alkyl is optionally substituted with
1-2 substituent groups independently selected from phenyl, -C(-0)0R6, ~OP(=0)(OR7)2, and -P(=O)(0R7)2, wherein phenyl is optionally substituted with one group -C(^O)OR7; and
(b) phenyl, which is substituted with 1-3 substituents independently selected from C1-C4 alkyl, -0Ci-C3alkyl, -C(=0)0R7, and cyclohexyl, wherein Ci-C4aikyl and -0C] -C3alkyl are optionally substituted with 1-2 groups independently selected from -N(R7)2, -C(=0)0R7, and
Figure imgf000008_0002
In some embodiments, Rό is selected from H, Ci~C2alkyI, and -CH2phenyI.
In some embodiments, R7 is selected from H and C] -C2alkyl.
A particularly preferred embodiment of this invention is directed to prodrugs for making the compound having formula III, including pharmaceutically acceptable salts thereof:
Figure imgf000008_0003
The prodrug that is converted to Compound III when it is administered to a patient has the formula IV, shown below, where X is as defined previously.
Figure imgf000009_0001
The prodrugs of Formula I and IV described above chemically eliminate the oxazolidinone-based drug under buffered conditions at a pH in the range of 7.0-8.0, and preferably at about 7.5, and at a temperature of about 37 0C (in the range of about 36-38 ° C).
These conditions are representative of the conditions that occur in the small intestine shortly after the contents of the stomach pass from the stomach into the small intestine. The drags that are produced by the cyclization reactions, compounds II and III, are potent inhibitors of CETP in humans and animals, and have been shown to raise HDL-cholesterol and reduce LDL-cholesterol in humans and in animals that have CETP genes. The compounds are expected to have utility in the treatment and prevention of atherosclerosis and associated diseases and disorders.
The compounds and the formulations of the compounds are useful in treating diseases which are characterized by low-HDL and/or high-LDL, or which can be treated or ameliorated by raising HDL and/or reducing LDL such as hypercholesterolemia, hyperlipidemia, and atherosclerosis. Furthermore, administration of the compounds and formulations described herein does not cause an increase in blood pressure as was observed for torcetrapib.
Doses of the prodrug in humans that will be therapeutically effective in raising HDL and lowering LDL are the amounts that are equivalent after cyclization to active drug in an amount in the range of 20mg to 200mg, such as for example 20mg, 25 mg, 30 mg, 40mg, 50mg, 60mg, 70 mg, 80 mg, 90 mg, 100 mg, l lOmg, 120mg, 130mg? 140mg, 150mg, 160mg, 180mg and 200mg, administered once or twice a day, but preferably once a day. A preferred dose will provide 100 mg of active drug and will be administered once a day.
The prodrugs provide improved bioavailability compared with conventional formulations of the active drug. Furthermore, conventional formulations comprising the CETP inhibitors that are made from the prodrugs herein exhibit a "food effect," which results in differences in the amount and rate of absorption into the body depending on when the patient was last fed, how soon the patient eats after oral administration of the drug, and whether the patient takes the drug before a meal, with a meal, or after a meal. The prodrug formulations disclosed herein should exhibit a reduced food effect compared with conventional formulatons because they cyclize to the active drag after the prodrug has passed into the small intestine, which is the site of absorption.
EXAMPLES
The following examples are provided to more fully illustrate the invention and are not to be construed as limiting the scope of the invention, which is defined only by the appended claims,
INTERMEDIATE 1
Figure imgf000010_0001
2,3,4-Trimethoxyphenol
A solution of 2,3,4-trimethoxybenzaldehyde (1,00 g, 5.10 mmol) and 30 wt/v % hydrogen peroxide (0.672 mL, 6.52 mmol) in cone. H2SO4 (0.102 mL) and MeOH (10.19 niL) was stirred overnight at 25 0C under N2. After this time the mixture was diluted with water (20 mL) and extracted with CH2Cl2 (3 x 30 mL). The combined extracts were dried (MgSO4) and concentrated in vacuo to afford the crude product. This was purified by flash chromatography (Biotage Horizon, 4OM, Si9 -30 niL/min, 100% hexanes for 360 mL, gradient to 50% EtOAc in hexanes over 2088 mL) to afford 2,3,4-trimethoxyphenol, as a colorless oil. R/ = 0.93 (50% EtOAc/hexanes). LCMS calc. = 185.1; found = 185.2 (M+H)+. 1H NMR (600 MHz, CDCl3): δ 6.62 (d, J- 9.0 Hz5 1 H); 6.55 (d, J= 8.9 Hz, 1 H); 5.49 (s, 1 H); 3.94 (s, 3 H); 3.89 (s, 3 H); 3.80 (s, 3 H).
The intermediates described in Table 1 were prepared using methods analogous to those described for INTERMEDIATE 1 starting from commercially available benzaldehydes.
TABLE 1
Figure imgf000010_0002
Figure imgf000011_0002
INTERMEDIATE 4
Figure imgf000011_0001
fert-Butyl (2^)-2-r(fer?-butoxycarbonyl)amino]-3-(4-hvdroxyphenyl)propanoate
A solution of di-fert-butyl dicarbonate (6.81 g, 31.2 mmol) in dry CH2Cl2 (15 mL) was added dropwise via cannula to a stirred solution of L-tyrosine tert-butyl ester (6.17 g, 26.0 mmol) and triethylamine (5.26 g, 7.25 mL, 52.0 mmol) al 0 0C under N2. The reaction was stirred at room temperature overnight. Water (30 mL) was added and the mixture was stirred for 30 min. The organic layer was washed with water (20 mL), 0.05 M HCl (20 mL), water (20 mL) and brine (20 mL), dried (MgSO4) and concentrated in vacuo to give the crude product. This was purified by flash chromatography (Biotage Horizon, 65i, Si, ~70 mL/min, 100% hexanes for 450 mL, gradient to 25% EtOAc in hexanes over 4446 mL, gradient to 40% EtOAc in hexanes over 2448 mL) to afford tert-bxxty\ (2S)-2-[(ferr-butoxycarbonyl)amino]-3-(4- hydroxyρhenyl)propanoate. R/ = 0.28 (20% EtOAc/hexanes). LCMS calc, = 360.2; found = 359,9 (M+Na)+. 1H NMR (500 MHz, CDCl3): δ 7.02 (d, J= 8.1 Hz, 2 H); 6.73 (d, J = 8.1 Hz, 2 H); 5.41 (s, I H); 4.99 (d, J= 7.9 Hz, 1 H); 4.40 (q, J- 6.6 Hz, 1 H); 3.01-2.93 (m, 2 H); 1.42 (s, 9 H); 1.41 (s, 9 H).
ΓNTERMEDIATE 5
Figure imgf000012_0001
fert-Butylι2-[(fer(:butoxycarbonyl)ammo]-3"(4-hvdroxy-3-methoxyphenyl)propaπoate Step A: 2-[(fer/-Butoxycarbonyl)amino]-3-f4-hvdroxy-3-methoxyphenyl)propanoic acid Triethylamine (719 mg, 980 μL, 7.10 mmol) was added to a solution of 3- methoxy-DL-tyrosine (1.00 g, 4.73 mmol) in 1 ,4-dioxane/water (1 :1, 17.2 mL). The solution was cooled to 0 0C and di-tert-butyl dicarbonate (1.14 g, 5.21 mmol) was added in one batch.
The reaction was warmed to room temperature and stirred for 3 days. The reaction mixture was concentrated in vacuo and the residue was diluted with water and EtOAc. The aqueous layer was washed with EtOAc, acidified to pH 1 with IN HCl and back extracted with EtOAc. The combined organic extracts were dried (MgSO4) and concentrated in vacuo to afford 2-[(tert- butoxycarbonyl)amino]-3-(4-hydroxy-3-methoxyphenyl)propanoic acid, as an off-white solid. LCMS calc. = 334.1 ; found - 333.8 (M+Na)+. 1U NMR (500 MHz, CDCl3): δ 6.77-6.67 (m, 3 H); 5.28 (d, J= 7.2 Hz, I H); 4.39 (dd, J= 5.8,12.4 Hz, 1 H); 3.83 (s, 3 H); 3.12 (dd, J- 5.3, 13.8 Hz, 2 H); 1.41 (s, 9 H); 1.35 (s, I H).
Step B: /erf-Butyl 2-f(fer?-butoxycarbonγl)aminol-3-(4-hvdroxy-3-methoxyρhenyl)ρropanoate
/-BuOH (5.17 g, 6.67 mL, 69.8 mmol) was added to a stirred suspension of 2- [(fcrt-butoxycarbonyl)amino]-3-(4-hydroxy-3-methoxyphenyl)propanoic acid (1.55 g, 4.98 mmol) in dry toluene (25 mL). The mixture was brought to reflux to give a homogeneous solution. iV,iV-dimethyIf.ormamide dineopentyl acetal (3.46 g, 4.17 mL, 15.0 mmol) was added dropwise over 1 h at reflux. After heating at reflux to 3-4 h, the reaction mixture was cooled to room temperature and a saturated solution OfNaHCO3 (40 mL) was added. The mixture was extracted with CHaCl2 (3 x 40 mL) and the combined extracts were dried (Na2SO4) and concentrated in vacuo to give the crude product. This was purified by flash chromatography (Biotage Horizon, 4OM, Si, -30 mL/min, 100% hexanes for 360 mL, gradient to 20% EtOAc in hexanes over 4536 mL) to afford (ert-butyl 2-[(ter?-butoxycarbonyl)amino]-3-(4-hydroxy-3- methoxyphenyl)propanoate. R/ = 0.42 (20% EtOAc/hexanes). LCMS calc. = 390.2; found = 389.9 (M+Na)+. 1H NMR (500 MHz, CDCl3): δ 6.82 (d, J= 7.9 Hz, 1 H); 6.87-6.63 (m, 2 H); 5.54 (s, 1 H); 4.97 (d, J = 7.8 Hz, 1 H); 4.40 (q, J- 6.7 Hz1 1 H); 3.86 (s, 3 H); 2.98 (d, J = 6.0 Hz, 2 H); 1.42 (s, 9 H); 1.41 (s, 9 H). INTERMEDIATE 6
Figure imgf000013_0001
(\R2S)- 1 -f 3,5-Bisftrifluoromethvnphenyl]-2-f ( r4'-fluoro-5'~isopropyI-2'-methoχy-4- (trifluoromethyl)biphenyl-2-yl1 methyl } amino)ρropan- 1 -ol
Potassium hydroxide (368.3 mg, 6.56 mmol) was added to a stirred solution of (4S,5R)-5-[3 ,5-bis(trifluoromethyl)phenyl]-3- { [41-fluoro-5'-isopropyl-2'-methoxy-4- (trifϊuoromethyl)biphenyI-2-yl]methyl}-4-methyl-l,3-oxazolidin-2-one (0.87 g, 1.36 mmol) in i- PrOH (44.7 mL) and water (9.0 mL) and the mixture was heated at 75 0C in a sealed tube overnight. The reaction was cooled to room temperature and concentrated in vacuo to remove most of the z'-PrOH. Brine (25 mL) was added and the mixture was extracted with EtOAc (3 x 50 mL). The combined extracts were dried (MgSO4) and concentrated in vacuo to afford (UJ25)-l-[3,5-bis(trifluoromethyl)phenyl]-2-({[4'-fluoro-5'-isopropyl-2'-methoxy-4- (trifluoromethyl)biphenyl-2-yl] methyl }amino)propan-l-ol, as a colorless solid. R/ = 0.49 (20% EtOAc/hexanes). LCMS calc. = 612.2; found = 611.8 (M+H)+. 1H NMR (500 MHz, CDCl3): δ 7.76-7.69 (m, 4 H); 7.60 (d, J- 7.8 Hz, 1 H); 7.33 (dd, J- 4.0, 7.9 Hz, 1 H); 7.00 (d, J= 8.5 Hz5 I H); 6.71 (dd, J= 5.9, 1 1.9 Hz3 I H); 4.74 (br d, J- 16.0 Hz, 1 H); 3.85-3.70 (m5 6 H); 3.26-3.18 (m, 1 H); 2.81-2.78 (m, 1 H); 1.28-1.20 (m, 7 H); 0.62 (d, J= 6.5 Hz, 3 H).
INTERMEDIATE 7
Figure imgf000013_0002
tert-Butyl Ul5.2igV2-r3.5-bisflriflttorome1faγl)phenvI1-2-hyάroxv-l-me1faγlethvU (f4'-fluoro-5'- isoρroργl-2'-methoxy-4-(lrifluoromethyl)biphenγl-2-γl1methyl}carbamate
Diisopropylethylamine (363 mg, 489 μL, 2.81 mmol) was added to a stirred solution of (1 R,2S)~ 1 -[3 ,5-bis(trifluoromethyl)phenyl]-2-( { [4'-fluoro-5'-isopropyl-2'-methoxy-4- (trifluoromethyl)biphenyl-2-yl]methyl}amino)propan-l-ol (858 mg, 1,40 mmol) in dry MeCN (16 niL) at room temperature under N2. The resulting solution was cooled to 0 0C and di-tert- butyldicarbonate (337 mg, 1.54 mmol) was added. The resulting mixture was warmed to room temperature and stirred for 2 days. The reaction mixture was diluted with Et2O (20 mL) and washed with water (10 mL) and brine (10 mL), dried (MgSO4) and concentrated in vacuo to give the crude product. This was purified by flash chromatography (Biotage Horizon, 25M, Si, -20 mL/min, 100% hexanes for 144 mL, gradient to 20% EtOAc in hexanes over 2880 mL) to afford tert-butyl {(15,2j?)-2-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxy-l-methylethyI} {[4'-fluoro-5'- isopropyl-2'-methoxy-4-(trifiuoromethyI)biphenyl-2-yl]methyl}carbamate, as a colorless solid. R/ = 0.63 (20% EtOAc/hexanes). LCMS calc. = 734.2; found - 733.9 (M+Na)+.
INTERMEDIATE 8
Figure imgf000014_0001
Dibenzyl 2-(4-hydroxyphenyl)ethyl phosphate
Step A: 4-(2-Bromoethyi)phenyl acetate
Acetyl chloride (2.01 g, 1 ,82 mL. 25.6 mmol) was added to a stirred solution of pyridine (2.02 g, 2.07 mL, 25.6 mmol) and 4-hydroxyphenethyl bromide (856.5 mg, 4.26 mmol) in dry CH2Ci2 (17 mL) and the reaction was stirred at room temperature for 2 h. The reaction mixture was diluted with water (20 mL) and extracted with CH2Cl2 (2 x 40 mL). The combined extracts were dried (MgSO4) and concentrated in vacuo to afford 4-(2-bromoethyl)phenyl acetate. 1H NMR (500 MHz, CHCl3): δ 7.22 (d, J- 8.3 Hz, 2 H); 7.04 (d, J= 8.3 Hz, 2 H);
3.55 (t, J= 7.6 Hz, 2 H); 3.16 (t, J= 7.6 Hz, 2 H); 2.29 (s, 3 H).
Step B: 4-f2-{[Bis(benzyloxγ)ρhosphoryl]oxy}ethyl)phenyl acetate
Silver dibenzylphosphate (2.08 g, 5.39 mmol) was added to a stirred solution of 4-
(2-bromoethyl)phenyl acetate (1.31 g, 5.39 mmol) in toluene (43 mL) and the mixture was heated at reflux overnight. The precipitate formed was removed by filtration through a plug of Celite. The filter cake was washed with toluene and the combined filtrates were concentrated in vacuo to give the crude product. This was purified by flash chromatography (Biotage Horizon, 4OM, Si, -30 mL/min, 100% hexanes for 360 mL, gradient Io 50% EtOAc in hexanes over 4536 mL) to afford 4-(2-{[bis(benzyloxy)phosphoryl]oxy}ethyl)phenyl acetate. R/ = 0.51 (50% EtOAc/hexanes). LCMS calc. - 441.1; found - 440.9 (M+H)+. 1H NMR (500 MHz, CHCl3): δ 7.37-7.30 (m, 10 H); 7.15 (d, J- 8.3 Hz, 2 H); 6.99 (d, J - 8.3 Hz, 2 H); 4.15 (q, J= 7.1 Hz, 2 H); 2.89 (t, J = 7.0 Hz, 2 H); 2.28 (s, 3 H).
Step C: Dibenzyl 2-(4-hydroxyphenyl)ethyl phosphate
Potassium carbonate (62.8 mg, 0.454 mmol) was added to a stirred solution of 4- (2-{[bis(benzyloxy)phosphoryl]oxy}ethyl)phenyl acetate (100 mg, 0.227 mmol) in MeOH (20.5 mL) at 25 0C. The reaction was stirred at 25 °C for 1 h. The reaction mixture was concentrated in vacuo and the resulting residue was partitioned between water (20 mL) and EtOAc (20 mL). The aqueous layer was separated and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried (MgSO4) and concentrated in vacuo to afford dibenzyl 2-(4- hydroxyphenyl)ethyl phosphate, as an oil. LCMS calc. - 399.1 ; found = 398.9 (M+H)+. 1H
NMR (500 MHz5 CHCl3): δ 8.05 (1 H, s); 7.41-7.30 (m, 10 H); 6.99 (d, J= 8.2 Hz, 2 H); 6.86 (d, J= 8.3 Hz, 2 H); 5.02 (s, 2 H); 5.00 (s, 2 H); 4.18 (q, J- 7.1 Hz5 2 H); 2.86 (t, J= 7.1 Hz, 2 H).
INTERMEDIATE 9
Figure imgf000015_0001
Dibenzyl 2-(4-hydroxy-3-methoxyphenoxy)ethyl phosphate Step A: 4-(2-Hydroxyethoxy)-2-methoxybenzaldehyde
A solution of 4-hydroxy-2-methoxybenzaldehyde (1.217 g, 8.00 mmol) in dry DMF (8.88 mL) was added to a stirred suspension of sodium hydride (60% dispersion in mineral oil) (0.267 mL, 8.00 mmol) in dry DMF (2.22 mL) via cannula at 0 0C under N2. The reaction mixture was stirred at 0 0C for 30 min and warmed to room temperature. 2-bromoethanol (0.851 mL, 12.00 mmol) was added dropwise and the reaction mixture was stirred at 50 0C overnight. The reaction was diluted with water (50 mL) and extracted with EtOAc (3 x 50 mL). The combined extracts were washed with IN aq. NaOH (50 mL), dried (MgSO4) and concentrated in vacuo to afford the crude product. This was purified by Dash chromatography (Biotage Horizon, 4OM, Si, -30 mL/min, 100% hexanes for 360 mL, gradient to 60% EtOAc in hexanes over 4536 mL) to afford 4-(2-hydroxyethoxy)-2-methoxybenzaldehyde, as a colorless solid. R/ = 0,29 (50% EtOAc/hexanes). LCMS calc. = 197.1; found = 197.0 (M+H)+. 1H NMR (500 MHz, CHCl3): δ 10.16 (s, 1 H); 7.68 (d, J= 8.7 Hz, 1 H); 6.46 (dd, J= 8.7, 2.2 Hz, 1 H); 6,40 (d, J = 2.2 Hz5 1 H); 4.09 (t, J = 4.6 Hz, 2 H); 3.94 (t, J = 4.4 Hz, 2 H); 3.79 (s, 3 H); 3.20 (s, 1 H).
Step B: 4-(2-Hvdroxyethoxy)-2-methoxvρhenol
A solution of 4-(2-hydroxyethoxy)-2-methoxybenzaldehyde (465.6 mg, 2.373 mmol) and 30 wt% hydrogen peroxide (0.313 mL, 3.04 mmol) in cone. H2SO4 (0.0475 mL) and MeOH (4.75 mL) was stirred overnight at 25 0C under N2. After this time the mixture was diluted with water (20 mL) and extracted with CH2Cl2 (3 x 30 mL). The combined extracts were dried (MgSO4) and concentrated in vacuo to afford the crude product. This was purified by flash chromatography (Biotage Horizon, 25M5 Si, -20 mL/min, 100% hexanes for 144 mL, gradient to 55% EtOAc in hexanes over 2394 mL, gradient to 100% EtOAc over 999 mL) to afford 4-(2- hydroxyethoxy)-2-methoxyphenol, as a colorless oil. R/ = 0.30 (50% EtOAc/hexanes). LCMS calc. = 207.1 ; found = 206.9 (M+Na)÷. 1U NMR (500 MHz, CHCl3): δ 6.77 (d, J- 8.6 Hz, 1 H); 6.47 (d, J = 2.8 Hz, 1 H); 6.34 (dd, J= 8.7, 2.8 Hz, 1 H); 5.82 (s, 1 H); 3.98 (t, J= 4.6 Hz, 2 H); 3.90 (t, J= 4.5 Hz, 2 H); 3.76 (s, 3 H); 2.96 (s, 1 H).
Step C: 4-(2-Hydroxyethoxy)-2-methoxyphenyl acetate
A solution of 1 -acetyl- IH-1 ,2,3-lriazolo[4,5-b]pyridine (0.248 g, 1.532 mmol) in dry THF (6.13 mL) was added to a solution of 4-(2-hydroxyethoxy)-2-methoxyphenol (0.2821 g, 1.532 mmol) in IN aq. NaOH (1.532 mL, 1.532 mmol) at 25 0C. The reaction was stirred at 25 0C for 3 h. The reaction was diluted with IN HCl (20 mL) and extracted with Et2O (3 x 20 mL). The combined extracts were dried (MgSO4) and concentrated in vacuo to afford the crude product. This was purified by flash chromatography (Biotage Horizon, 25M, Si, -20 mL/min, 100% hexanes for 144 mL, gradient to 50% EtOAc in hexanes over 360 mL, gradient to 100% EtOAc over 2034 mL) to afford 4-(2-hydroxyethoxy)-2-methoxyphenyl acetate. R/ = 0.28 (50% EtOAc/hexanes). LCMS calc. - 249.1 ; found = 249.0 (M+Na)+. 1H NMR (500 MHz, CHCl3): δ 6.87 (d, J= 8.7 Hz, 1 H); 6.52 (d, J= 2.7 Hz5 1 H); 6.38 (dd, J= 8.7, 2.7 Hz, 1 H); 3.96 (t, J = 4.7 Hz, 2 H); 3.84 (t, J- 4.7 Hz, 2 H); 3.71 (s, 3 H); 2.97 (s, 1 H); 2.24 (s, 3 H).
Step D: 4-(2-Bromoethoxy)-2-methoxyphenyl acetate
A solution of triphenylphosphine (0.123 mL, 0.530 mmol) in dry CH2CI2 (1.3 mL) was added dropwise via cannula to a stirred solution of 4-(2-hydroxyethoxy)-2-methoxyphenyl acetate (100 mg, 0.442 mmol) and carbon tetrabromide (0.051 mL, 0.530 mmol) in dry CH2Cl2 (3.0 mL) at 0 0C under N2. After 5 h at 0 0C, the reaction mixture was concentrated in vacuo and the residue obtained was purified by flash chromatography (Biotage Horizon, 25M, Si, ~20 niL/min, 100% hexanes for 144 mL, gradient to 50% EtOAc in hexanes over 1 125 mL) to afford 4-(2-bromoethoxy)-2-methoxyphenyl acetate, as a colorless oil. R/ - 0.78 (50% EtOAc/hexanes). LCMS calc. - 289.1; found - 288.8 (M+H)+. 1H NMR (500 MHz, CHCl3): δ 6.93 (d, J= 8.7 Hz, I H); 6.57 (d, J= 2.8 Hz, 1 H); 6.42 (dd, J- 8.7, 2.8 Hz, 1 H); 4.26 (t, J= 6.2 Hz, 2 H); 3.80 (s, 3 H); 3.62 (t, J= 6.2 Hz, 2 H); 2.29 (s, 3 H).
Step E: 4-(2-{ |"Bis(benzγloxy)phosphoryl]oxy|ethoxy)-2-methoxvphenvl acetate
Silver dibenzylphosphate (134 mg, 0.348 mmol) was added to a solution of 4-(2- bromoethoxy)-2-methoxyphenyl acetate (100.6 mg, 0.348 mmol) in toluene (2.762 mL) and the mixture was heated at reflux overnight. The precipitate formed was removed by filtration through a plug of Celite and washed through with toluene. The filtrate was concentrated in vacuo to give the crude product. This was purified by flash chromatography (Biotage Horizon, 2OM, Si5 -20 mL/min, 100% hexanes for 144 mL, gradient to 70% EtOAc in hexanes over 1 125 mL, gradient to 100% EtOAc over 999 mL) to afford 4-(2-
{[bis(benzyloxy)phosphoryl]oxy}ethoxy)-2-methoxyphenyl acetate, as a colorless oil. R/ = 0.26 (50% EtOAc/hexanes). LCMS calc. - 487.2; found = 486.9 (M+H)+. 1H NMR (500 MHz, CHCl3): δ 7.35-7.31 (m, 10 H); 6.91 (d, J= 8.7 Hz5 1 H); 6.50 (d, J= 2.7 Hz5 1 H); 6.37 (dd, J = 8.7, 2.7 Hz5 1 H); 5.12-5.02 (m, 4 H); 4.33-4.28 (m, 2 H); 4.07 (t, J = 4.6 Hz, 2 H); 3.73 (s, 3 H); 2.28 (s, 3 H).
Step F: Dibenzyl 2-(4-hydroxy-3-methoxyphenoxy)ethγl phosphate
Potassium carbonate (0.072 g, 0.524 mmol) was added to a stirred solution of 4- (2-{[bis(benzyloxy)phosphoryl]oxy}ethoxy)-2-methoxyρhenyl acetate (0.1274 g, 0.262 mmol) in MeOH (17.5 mL) at 25 0C. The reaction was stirred at 25 0C for 1 h. The reaction mixture was concentrated in vacuo and the resulting residue was partitioned between water (20 mL) and EtOAc (20 mL). The aqueous layer was separated and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried (MgSO4) and concentrated in vacuo to afford dibenzyl 2- (4-hydroxy-3-methoxyphenoxy)ethyl phosphate, as an oil. LCMS calc. = 445.1; found = 444.9 (M+H)+.
INTERMEDIATE 10
Figure imgf000018_0001
Methyl 5-f 3- { [bis(benzyloxy)phosphoryl1oxy}ρropyl)-2-hydroxy-3-methylbenzoate Step A: Methyl 2-hydroxy-5-iodo-3~methylbenzoate Methyl 2-hydroxy~3-methylbenzoate (0.869 g, 5.23 mmol) in MeOH (5 niL) was added dropwise to a suspension of iodine (1.327 g, 5.23 mmol) and silver sulfate (1.63 g, 5.23 mmol), at room temperature under N2. The resultant brown suspension was stirred for 3 h after which time a colorless suspension was observed. The mixture was filtered through a plug of Celite, washed with MeOH (30 mL) and concentrated in vacuo to afford methyl 2-hydroxy-5- iodo-3-methylbenzoate, as a colorless solid. LCMS calc. = 292.1 ; found - 292.7 (M+H)+ . ' H NMR (SOO MHz, CHCl3): δ 11.0 (s, 1 H); 8.02 (s, 1 H); 7.62 (s, 1 H); 3.97 (s, 3 H); 2.25 (s, 3 H).
Step B: Methyl 2-(acetyloxy)-5 -iodo-3-methylbenzoate To a stirred suspension of 2-hydroxy-5 -iodo-3-methylbenzoate (1.24 g, 4.25 mmol) in neat acetic anhydride (1.803 mL, 19.10 mmol) was added a 3 drops of concentrated sulfuric acid (0.226 mL, 4.25 mmol). The resultant orange solution was stirred at room temperature overnight. The solution was diluted with 3% aqueous NaHCO3 (13 mL) and extracted with CHCl3 (3 x 30 mL). The combined organic phases were washed with water (4 x 20 mL), dried (MgSO4), and concentrated in vacuo to afford methyl 2-(acetyloxy)~5-iodo-3- methylbenzoate, as a colorless solid. 1H NMR (500 MHz5 CHCl3): δ 8.17 (s, 1 H); 7.78 (s, 1 H); 3.89 (s, 3 H); 2.25 (s, 3 H); 2.21 (s, 3 H).
Step C: Methyl 2-(acetyIoxy)-5-(3-hydroxyprop-l-yn-l-yl)-3-rnethy.lbenzpate Triethylamine (0.943 mL, 6.76 mmol) and bis(triphenylphosphine)palladium(ΪI) chloride (0.092 g, 0.132 mmol) were added to a mixture of methyl 2-(acetyloxy)-5-iodo-3- methylbenzoate (1.0 g5 2.99 mmol) and propargyl alcohol (0.161 mL, 2.69 mmol) in THF (20 mL) at room temperature, and then copper (I) iodide (0.053 g, 0.278 mmol) was added. The resulting mixture was stirred at room temperature for 18 h. The reaction was quenched with water (20 mL) and extracted with EtOAc (3 x 30 mL). The combined organic extracts were washed with water (50 mL), brine (40 mL), dried (MgSO4), and concentrated in vacuo to give the crude product. This was purified by flash chromatography (Si, 0-20% EtOAc in hexanes over 30 min) to afford methyl 2-(acetyloxy)~5-(3-hydroxyprop-l-yn-l-yl)-3-methylbenzoate, as a yellow solid. 1H NMR (500 MHz, CHCl3): δ 7.97 (s, 1 H); 7.53 (s, 1 H); 4.91 (s, 2 H); 3.88 (s, 3 H);
2.22 (s, 3 H); 2.16 (s, 3 H).
Step D: Methyl 2-(acetyloxy)-5-[(l^-3-hydroxyprop-l-en-l-yI]-3-methylbenzoate A suspension of methyl 2~(acetγIoxy)-5-(3-hydroxyprop-l-yn-l-yl)-3- methylbenzoate (0.417 g, 1.590 mmol) and palladium on carbon (170 mg, 1.597 mmol) in EtOAc (20 mL) was stirred at room temperature under a balloon atmosphere of H2 for 3 days. The reaction mixture was filtered through a plug of Celite and washed through with EtOAc (3x30 mL). The filtrate was concentrated in vacuo to give the crude product. This was purified by flash chromatography (Si, 0-20% EtOAc in hexanes over 40 min) to afford methyl 2-
(acetyloxy)-5-[(lZ)-3-hydroxyproρ-l-en-l-yl]-3-methylbenzoate> as a pale yellow oil. 1H NMR (500 MHz, CHCl3); δ 7,69 (s, 1 H); 7.29 (s, 1 H); 6.53 (d, J - 12 Hz, 1 H); 5.94 (m, 1 H); 4.44 (d, J- 6.4 Hz, 2 H); 3.88 (s, 3 H); 2.40 (s, 3 H); 2.25 (s, 3 H).
Step E: Methyl 2-facetyloxy)-5-(3-hydroxypropyl)-3-methylbenzoate
A suspension of 10% palladium on carbon (146 mg, 0.137 mmol) in a solution of methyl 2-(acetyloxy)-5-[(lZ)-3-hydroxyprop~l~en-l-yl]-3-methylbenzoate (362 mg, 1.370 mmol) in EtOAc (17.2 mL) was shaken in a Parr shaker under H2 at 40 psi overnight. The reaction mixture was filtered through a plug of Celite and washed through with EtOAc. The filtrate was concentrated in vacuo to afford the crude product. This was purified by flash chromatography (Biotage Horizon, 25M3 Si, -20 mL/min, 100% hexanes for 144 mL, gradient to 60% EtOAc in hexanes over 1125 mL) to afford methyl 2-(acetyloxy)-5-(3-hydroxyproρyl)-3-methylbenzoate, as a colorless oil, LCMS calc. = 289.1; found = 288.9 (M+Na)÷. 1H NMR (500 MHz5 CHCl3): δ 7.65 (d, J= 2.2 Hz, 1 H); 7.25 (d, J- 2.2 Hz, 1 H); 3.84 (s, 3 H); 3.64 (t, J- 6.4 Hz, 2 H); 2.67 (t, J= 7.8 Hz, 2 H); 2.35 (s, 3 H); 2.18 (s, 3 H); 1.89-1.82 (m, 2 H).
Step, F: Methyl 2-(acetyloxy)-5-(3-{|"bis(benzylρxy)phosphoryl]oxy)propyl)-3-methylbenzoate
Dibenzyl N,N-diisoproρylρhosphoramidite (0.252 mL, 0.751 mmol) was added to a stirred solution of lH-tetrazole (3 wt% in CH3CN) (4.40 mL, 1.502 mmol) and methyl 2- (acetγloxy)-5-(3-hydroχypropy!)-3-methylbenzoate (100 mg, 0.376 mmol) in dry CH2Cl2 (4.50 mL) at 25 0C under N2. The reaction was stirred for 2 h at 25 0C. After this time another 0.5 eq dibenzyl N,N-diisopropylphosphoramidite was added and the reaction was stirred for 30 min. The reaction mixture was cooled to 0 0C and a solution of 3-chloroperoxybenzoic acid (337 mg, 1.502 mmol) in dry CH2Cl2 (3,00 mL) was added via cannula. After 30 min another 1 eq 3- chloroperoxybenzoic acid was added and the reaction was stirred at 0 0C. After 30 min the reaction was diluted with EtOAc (30 mL) and washed with successive portions of saturated Na2SO3 (20 mL) and saturated NaHCO3 (20 mL), dried (MgSO4) and concentrated in vacuo to give the crude product. This was purified by flash chromatography (Biotage Horizon, 25M, Si, ~20 niL/min, 100% hexanes for 144 mL, gradient to 60% EtOAc in hexanes over 2394 mL) to afford methyl 2-(acetyloxy)-5-(3-{[bis(benzyloxy)phosphoryl]oxy}propyl)-3-methylbenzoate, as a colorless oil. LCMS calc. - 527.2; found = 527.0 (M+H)+. 1H NMR (500 MHz, CHCl3): δ 7.62 (d, J= 2.2 Hz, 1 H); 7.36-7.31 (m, 10 H); 7.18 (d, J = 2.2 Hz5 1 H); 5.11-4.98 (m, 4 H); 4.00 (q, J= 6.6 Hz, 2 H); 3.84 (s, 3 H); 2.61 (t, J= 7.8 Hz, 2 H); 2.36 (s, 3 H); 2.17 (s, 3 H); 1.93-1.85 (m, 2 H).
Step G : Methyl , 5 -(3 - { [bis(benzyloxy)phosphoryl] oxy } propyl)-2-hydroxy-3 -methylbenzoate K2CO3 (108 mg, 0.784 mmol) was added to a stirred solution of methyl 2-
(acetyloxy)-5-(3-{[bis(benzyloxy)phosphoryl]oxy}propyl)-3-methylbenzoate (206.3 mg, 0.392 mmol) in MeOH (26.1 mL) at 25 0C. The reaction was stirred at 25 0C for 1 h. The reaction mixture was concentrated in vacuo and the resulting residue was partitioned between water (20 mL) and EtOAc (20 mL). The aqueous layer was separated and extracted with EtOAc (2 x 20 mL), The combined organic extracts were dried (MgSO4) and concentrated in vacuo to afford methyl 5-(3-{[bis(benzyloxy)phosphoryl]oxy}propyl)-2-hydroxy-3-methylbenzoate, as a colorless oil. LCMS calc. = 485.2; found = 485.0 (M+H)+.
INTERMEDIATE 11
Figure imgf000020_0001
Dibenzyl 2 -hydroxy ethyl phosphate
To a stirred solution of 2-bromoethanol (200 mg, 1.600 mmol) in anhydrous toluene (15 mL) was added silver dibenzylphosphate (616 mg, 1.600 mmol) and the resultant mixture was heated at reflux for 4 h. The reaction mixture was filtered through Celite, and washed through with additional toluene (2 x 25 mL). The combined organic extracts were concentrated in vacuo and the resulting crude product purified by flash chromatography (75% EtOAc/hexanes) to afford dibenzyl 2-hydroxyethyl phosphate, as a colorless oil.
INTERMEDIATE 12
Figure imgf000021_0001
Dibenzyi 2-(4-hvdroxy-3-isopropoxyphenoxy)ethyl phosphate Step A: 4~(Benzyloxy)-2-isopropoxybenzaldehyde K2CO3 (9.62 g. 69.6 mmol) and 2-iodopropane (2,00 niL, 20.00 mmol) were added successively to a stirred solution of 4-benzyϊoxy-2-hydroxybenzaldehyde (3.65 g, 16.0 mmol) in dry DMF (20.0 niL) at 25 0C under N2. The reaction was heated at 50 0C overnight. The reaction was diluted with water (50 mL) and extracted with Et2O (3 x 50 mL). The combined extracts were dried (MgSO4) and concentrated in vacuo to afford 4-(benzyloxy)-2- isopropoxybenzaldehyde. LCMS calc. = 293.1 ; found = 292.9 (M+Na)+.
Step B: 4~Hydroxy-2-isopropρxybenzaldehyde
A suspension of 10% palladium on carbon (0.793 g, 0,745 mmol) in a solution of 4-(benzyloxy)-2-isopropoxybenzaldehyde (4.03 g, 14.91 mmol) and 1 -methyl- 1,4- cyclohexadiene (16.75 mL, 149 mmol) in EtOH (298 mL) was heated at reflux for 2 h. The reaction mixture was cooled to room temperature, filtered through a plug of Celite and washed through with EtOAc. The filtrate was concentrated in vacuo to afford 4-hydroxy-2- isopropoxybenzaldehyde, as a colorless solid. LCMS calc. = 181.1 ; found = 181.0 (M+H)+. !H NMR (500 MHz, CHCl3): δ 10.12 (s, IH); 7.74 (d, J= 8.6 Hz, 1 H); 6.52 (dd, J= 8.7, 2.1 Hz5 1 H); 6.47 (d, J- 2.1 Hz, 1 H); 4.62-4.54 (m, 1 H); 1.36 (d, J = 6.1 Hz, 6 H).
4-Hydroxy-2-isopropoxybenzaldehyde was used to synthesize dibenzyi 2-(4-hydroxy-3- isopropoxyphenoxy)ethyl phosphate using methods analogous to those described in INTERMEDIATE 9 and 10 above.
INTERMEDIATE 13
Figure imgf000021_0002
Dibenzyi (3 -hydroxypropy Pphosphonate Step A: Dibenzyl [3-ftetrahydro-2H-pwan-2-yloxy)propyl]phosphonate
Dibenzyl phosphite (1.70 mL, 7.63 mmol) was added to a stirred suspension of sodium hydride (60% dispersion in mineral oil) (0.381 g, 9.53 mrnol) in dry DMF (11.4 mL) at 25 0C under N2. After 15 min 2-(3-bromopropoxy)tetrahydro-2//-pyran (1.29 mL, 7.63 mmol) was added and the mixture was stirred at 25 °C for 5 h. The reaction mixture was diluted with water (20 mL) and extracted with Et2O (2 x 40 mL). The combined organic extracts were washed with brine (20 mL), dried (Na2SO4) and concentrated in vacuo to afford dibenzyl [3- (tetrahydro-2//-pyran-2-yloxy)propyl]phosphonate. R/ = 0.06 (20% EtOAc/hexanes). LCMS calc. = 427.17; found - 427.15 (M+Naf.
Step, B: Dibenzyl (3-hydroxypropyl)phosphonate
A solution of dibenzyl [3-(tetrahydro-2//-pyran-2-yloxy)propyl]phosphonate (3.08 g, 7.62 mmol) and pyridinium/j-toluenesulfonate (0.191 g, 0.762 mmol) in EtOH (76 mL) was stirred at 55 0C overnight. The reaction mixture was cooled to room temperature and concentrated in vacuo to give the crude product. This was purified by flash chromatography
(Biotage Horizon, 4OM, Si, -30 mL/min, 100% hexanes for 360 mL, gradient to 100% EtOAc in hexanes over 3096 mL, 100% EtOAc for 3888 mL) to afford dibenzyl (3- hydroxypropyϊ)phosρhonate. R/ = 0.34 (EtOAc). LCMS calc. - 321.13; found = 321.04 (M+H)+. 1H NMR (500 MHz, CHCl3): δ 7.35-7.28 (m, 10 H); 5.02 (dd, J= 11.9, 8.9 Hz, 2 H); 4.94 (dd, J= 11.9, 8.0 Hz, 2 H); 3.60 (t, J= 5.6 Hz, 2 H); 3.37 (s, 1 H); 1.90-1.75 (m, 4 H).
INTERMEDIATE 14
Figure imgf000022_0001
Tetrabenzyl 2-(2-hydroxyethoxy)ρropane-l,3-diyl bisf phosphate)
Step A: 2-Phenyl-5-[2-(tetrahvdro-2/f-pyran-2-yloxy)ethoxy]-l ,3-dioxane
Sodium hydride (60% disp. in mineral oil) (0.666 g, 16.65 mmol) was added to a stirred solution of 1,3-benzylidene glycerol (1.00 g5 5.55 mmol) in dry DMF (13.9 mL). The reaction mixture was stirred at room temperature for 1 h. 2~(2-bromoethoxy)tetrahydro-2//- pyran (1.26 mL, 8.32 mmol) was added dropwise and the reaction mixture was stirred at room temperature overnight. The reaction was diluted with CH2Cl2 (50 mL) and washed with water (50 mL). The aqueous layer was washed with CH2Cl2 (25 mL). The combined organic layers were washed with brine (50 mL), dried (MgSO4) and concentrated in vacuo to give the crude product. This was purified by flash chromatography (Biotage Horizon, 4OM, Si, -30 mL/min, 100% hexanes for 360 mL, gradient to 50% EtOAc in hexanes over 4536 mL) to afford 2- phenyl- 5 -[2-(tetrahydro-2H~ρyran~2-yIoxy)ethoxy]-l ,3-dioxane, as a colorless oil. R/ = 0.54 (50% EtOAc/hexanes). LCMS calc. = 309.17; found - 309.05 (M+H)+.
Step B: 2-[2-(Tetrahydro-2//-ρyran-2-yloxy)ethoxy]propane-K3-diol
A suspension of 10% palladium on carbon (172 mg, 0.162 mmol) in a solution of 2-phenyl-5-[2-(telrahydro-2//-pyran-2-yloxy)ethoxy]-lf3-dioxane (498.9 mg, 1.618 mmol) in EtOAc (32.4 mL) was stirred under H2 at 25 0C for 3 days. The reaction mixture was filtered through a plug of Celite and the filtrate was concentrated in vacuo to afford 2-[2-(tetrahydro-2H- pyran-2-yloxy)ethoxy]propane-l,3-diol. LCMS calc. = 243.12; found = 243.22 (M+Na)+.
Step C: Tetrabenzyl 2-|"2-(tetrahydro-2/i-ρyran-2-yloxy)ethoxy]propane-l,3-diylbis(phosρhate) Dibenzyl N,N-diisoρropylρhosρhoramidite (1.43 mL, 4.26 mrnol) was added to a stirred solution of ltf-tetrazole (0.45 M in CH3CN) (18.9 mL, 8.52 mmol) and 2-[2-(tetrahydro~ 2H-pyran-2-yloxy)ethoxy] propane- 1, 3 -diol (312.6 mg, 1.419 mmol) in dry CH2Cl2 (17.0 mL) at 25 0C under N2. The reaction was stirred for 2 h at 25 0C. The reaction mixture was cooled to 0 0C and a solution of 3-chloroperoxybenzoic acid (1272 mg, 5.68 mmol) in dry CH2Cl2 (11.4 mL) was added via cannula and the reaction was stirred at 0 0C. After 60 min the reaction was diluted with EtOAc (50 mL) and washed with successive portions of saturated Na2SO3 (50 mL) and saturated NaHCO3 (50 mL), dried (Na2S O4) and concentrated in vacuo to afford the crude product. This was purified by flash chromatography (Biotage Horizon, 4OM, Si, -30 mL/min, 100% hexanes for 360 mL, gradient to 100% EtOAc over 4536 mL) to afford tetrabenzyl 2-[2- (tetrahydro -2H-pyran-2-yloxy)ethoxy] propane- 1 ,3-diylbis(phosphate), as a colorless oil. R/ = 0.64 (EtOAc). LCMS calc. - 763.24; found = 763.21 (M+Na)+. 1H NMR (500 MHz, CHCI3): δ 7.39-7..27 (m, 20 H); 5.11-4.94 (m, 8 H); 4.52 (br s, 1 H); 4.14-3.95 (m, 4 H); 3.80-3.59 (m, 5 H); 3.51-3.34 (m, 2 H); 1.76-1.59 (m, 2 H); 1.52-1.47 (m, 2 H); 1.45 (br s, 2 H).
Step D: Tetrabenzyl 2-(2-hydroxyethoxy)proρane-l,3-diyl bis(phosphate)
A solution of tetrabenzyl 2-[2-(tetrahydro-2H-pyran-2-yloxy)ethoxy]propane-l,3- diylbis(phosphate) (84,3 mg, 0.114 mmol) and pyridinium p-toluenesulfonate (2.86 mg, 0.01 1 mmol) in EtOH (1.14 mL) was stirred at 55 0C for 4 h. The reaction mixture was cooled to room temperature and diluted with EtOAc (25 mL), washed with saturated NaHCO3 (10 mL), dried (Na2SO4) and concentrated in vacuo to afford tetrabenzyl 2-(2-hydroxyethoxy)propane-l,3-diyl bisφhosphate). LCMS calc. - 657.20; found = 657.06 (M+H)+. 1H NMR (500 MHz, CHCl3): δ 7.40-7.28 (m, 20 H); 5.10-4.95 (m, 8 H); 4.14-4.04 (m, 2 H); 4.03-3.92 (m, 2 H); 3.76-3.67 (m, 1 H); 3.67-3.56 (m, 2 H); 3.57-3.44 (m, 2 H).
INTERMEDIATE 15
Tetrabenzyl 2-(4~hydroxy-3-isoprppoxyphenoxy)propane- 1.3-diylbisC phosphate)
Step A: 4-(Benzyloxy)-2-isopropoxybenzaldehydc K2CO3 (6.14 g, 44.4 mmol) and 2-iodopropane (1.28 mL, 12.76 mmol) were added successively to a stirred solution of 4-benzyloxy-2-hydroxybenzaldehyde (2.33 g, 10.21 mmol) in dry DMF (12.8 mL) at 25 0C under N2. The reaction was heated at 50 0C overnight.
The reaction was diluted with water (50 mL) and extracted with Et2O (3 x 50 mL). The combined extracts were dried (MgSO4) and concentrated in vacuo to afford the crude product. This was azeotroped from toluene to afford 4-(benzyloxy)-2-isopropoxybenzaldehyde. LCMS calc. = 293.1 ; found = 292.9 (M+Na)+.
Step B: 4-(Benzγloxy)-2-isopropoxγphenol
A solution of 4-(benzyloxy)-2-isopropoxybenzaldehyde (2.76 g, 10.21 mmol) and 30 wt% hydrogen peroxide (1.35 mL, 13.07 mmol) in cone. H2SO4 (0.204 mL) and MeOH (20.4 mL) was stirred for 3 h at 25 0C under N2. After this time the mixture was diluted with water (20 mL) and extracted with CH2Cl2 (3 x 30 mL). The combined extracts were dried (MgSO4) and concentrated in vacuo to afford 4-(benzyloxy)-2-isopropoxyphenol, as a colorless oil. LCMS calc. = 281.1 ; found - 281.0 (M+Na)+.
Step C: 4-(Benzyloxy)-2-isopropoxyphenyl benzoate
Triethylamine (4.27 mL, 30.7 mmol) was added to a solution of 4-(benzyloxy)-2- isopropoxyphenol (2.64 g, 10.22 mmol) in dry CH2Cl2 (40.9 mL) and the resulting solution was cooled to 0 0C. Benzoyl chloride (1.54 mL, 13.29 mmol) was added dropwise and the reaction was stirred at 25 0C overnight. The reaction mixture was washed with water (50 mL). The aqueous layer was separated and extracted with CH2Cl2 (2 x 20 mL). The combined organic layers were dried (MgSO^ and concentrated in vacuo to give the crude product. This was azeoptoped with toluene to afford 4-(benzyloxy)-2-isopropoxyphenyl benzoate. LCMS calc. = 385.1 ; found - 385.0 (M+Na)+. 1H NMR (500 MHz, CHCl3): δ 8.25-8.21 (2 H, m), 7.66-7.60 (1 H, m), 7.52 (2 H51, J- 7.7 Hz), 7.47 (2 H, d, J = 7.5 Hz), 7.44-7.39 (2 H, m), 7.39-7.33 (1 H, m), 7.12-7.05 (1 H, m), 6.73-6.68 (1 H, m), 6.60 (1 H, dd, J- 8.7, 2.8 Hz), 5.07 (2 H, s), 4.54-4.43 (1 H, m), 1.27 (6 H, t, J= 6.1 Hz).
Step D: 4-Hydroxy-2-isoproρoxyphenyl benzoate
A suspension of 10% palladium on carbon (0.543 g, 0.510 nimol) in a solution of 4-(benzyloxy)-2-isopropoxyphenyl benzoate (3.70 g, 10.21 mmol) in EtOAc (25 mL) and EtOH (5 mL) was shaken in a Parr shaker under H2 (45 psi) at 25 °C for 3 days. The reaction mixture was filtered through a plug of Celite and the filtrate was concentrated in vacuo to afford the crude product. This was purified by flash chromatography (Biotage Horizon, 40M5 Si, -30 mL/min, 100% hexanes for 360 mL, gradient to 25% EtOAc in hexanes over 4536 mL) to afford 4- hydroxy-2-isoρropoxyphenyl benzoate. R/ = 0.28 (20% EtOAc in hexanes). LCMS calc. = 295.10; found = 295.07 (M+Na)+. 1H NMR (500 MHz, CHCl3): δ 8.22 (d, J = 7.8 Hz5 2 H); 7.64 (t, J= 7.4 Hz, 1 H); 7.51 (t, J- 7.7 Hz, 2 H); 6.94 (d, J= 8.6 Hz, 1 H); 6.49 (d, J= 2.7 Hz5 I H); 6.35 (dd, J= 8.6, 2.7 Hz, I H); 4.39 (p, J- 6.1 Hz, 1 H); 1.22 (d, J- 6.1 Hz, 6 H).
Step E: 2-Isoproρoxy-4-[(2-phenyl-l,3-dioxan-5-yl)oxy]phenyl benzoate Diethyl azodicarboxylate (173 μL, 1.102 mmol) was added to a stirred solution of
4-hydroxy-2-isopropoxyphenyl benzoate (200 mg, 0.734 mmol), 1 ,3-benzylidene glycerol (159 mg, 0.881 mmol) and triphenylphosphine (289 mg, 1.102 mmol) in dry THF (7.34 mL) at room temperature under N2 The reaction was heated at reflux overnight, Another 1.5 eq of Ph3P and DEAD were added and the reaction was heated at reflux for another 5 h. The reaction mixture was concentrated in vacuo to afford the crude product. This was purified by flash chromatography (Biotage Horizon, 25M, Si, -20 mL/min, 100% hexanes for 144 mL, gradient to 25% EtOAc in hexanes over 2394 mL) to afford 2-isopropoxy-4-[(2-phenyl-l,3-dioxan-5- yl)oxy] phenyl benzoate, as a colorless solid. R/ - 0.67 (20% EtOAc in hexanes). LCMS calc. = 435.18; found = 435.18 (M+H)+. 1H NMR (500 MHz, CHCl3): δ 8.26 (d, J= 7.8 Hz, 2 H); 7.66 (U J= 7-5 Hz, 1 H); 7.60-7.51 (m, 4 H); 7.47-7.39 (m, 3 H); 7.12 (d, J= 8.7 Hz, 1 H); 6.68 (d, J= 2.8 Hz, I H); 6.63 (dd, J= 8.7, 2.7 Hz, 1 H); 5.56 (s, I H); 4.68-4.57 (m, 3 H); 4.53 (p, J = 6.1 Hz5 I H); 3.87 (t, J- 9.8 Hz, 2 H); 1.31 (d, J= 6.1 Hz, 6 H).
Step F: 4-r2-Hydroxy-l-(hydroxymethyl)ethoxy]-2-isopropoχyphenyl benzoate A suspension of 10% palladium on carbon (38.9 mg, 0.037 mmol) in a solution of
2~isopropoxy-4-[(2-phenyl-l,3-dioxan-5-yl)oxy]phenyl benzoate (158.7 mg, 0.365 mmol) in EtOAc (3.65 mL) was stirred under H2 (double balloon pressure) at 25 0C for 4 days. The reaction mixture was filtered through a plug of Celite and the filtrate was concentrated in vacuo to afford the crude product. This was purified by flash chromatography (Biotage Horizon, 25 M, Si, -20 mL/min, 100% hexanes for 144 mL, gradient to 100% EtOAc over 2394 mL) to afford 4- [2-hydroxy-l-(hydroxymethyl)ethoxy]-2-isoρropoxyphenyl benzoate, as a colorless solid. R/ = 0.17 (50% EtOAc in hexanes). LCMS calc. = 347.15; found = 347.06 (M+H)+. 1H NMR (500 MHz, CHCl3): δ 8.18 (d, J= 7.8 Hz, 2 H); 7.61 (t, J- 7.5 Hz, 1 H); 7.49 (t, J= 7.7 Hz, 2 H); 7.03 (d, J- 8.7 Hz3 I H); 6.68 (d, J= 2.7 Hz5 1 H); 6.56 (dd, J = 8.8, 2.7 Hz, 1 H); 4.45 (p, J = 6.1 Hz5 1 H); 4.34 (p, J= 4.8 Hz, 1 H); 3.89-3.80 (m, 4 H); 2.88 (s, 2 H); 1.23 (d, J = 6.1 Hz, 6 H).
Step G: 4-[2-{[Bis(benzyloxy)phosphoryl)oxy}-l- (/{[bis(benzylρxy)phosphoryl]oxy}methyl)ethoxy1-2-isoρropoxyphenyl benzoate
Dibenzyl N,N-diisopropylphosphoramidite (258 μL, 0.769 mmol) was added to a stirred solution of ltf-tetrazole (0.45 M in CH3CN) (3418 μL, 1.538 mmol) and 4-[2-hydroxy-l- (hydroxymethyl)ethoxy]-2-isopropoxyphenyl benzoate (88.8 mg, 0.256 rnmol) in dry CH2Cl2 (9.50 mL) at 25 0C under N2. The reaction was stirred for 3 h at 25 0C, The reaction mixture was cooled to 0 0C and a solution of 3-chloroperoxybenzoic acid (230 μL, 1.025 mmol) in dry CH2Cl2 (4.75 mL) was added via cannula and the reaction was stirred at 0 0C. After 60 min the reaction was diluted with EtOAc (25 mL) and washed with successive portions of saturated Na2SO3 (20 mL) and saturated NaHCO3 (20 mL), dried (Na2SO4) and concentrated in vacuo to afford the crude product. This was purified by flash chromatography (Biotage Horizon, 25M5 Si, -20 mL/min, 100% hexanes for 144 mL, gradient to 75% EtOAc in hexanes over 2394 mL) to afford 4- [2- { [bis(benzyloxy)phosphoryl ] oxy } - 1 - ({[bis(benzyloxy)phosphoryl]oxy}methyl)ethoxy]-2-isopropoxyphenyl benzoate, as a colorless oil. R/ = 0.41 (50% EtOAc in hexanes). LCMS calc. - 867.27; found = 867.14 (M+H)"1. 1H NMR (500 MHz5 CHCl3): δ 8.20 (d, J- 7.7 Hz, 2 H); 7.63 (t, J- 7.5 Hz, 1 H); 7.51 (t, J- 7.7 Hz, 2 H); 7.44-7.20 (m, 20 H); 6.98 (d, J- 8.7 Hz, 1 H); 6.61 (d, J= 2.8 Hz, 1 H); 6.44 (dd, J - 8.7, 2.8 Hz5 1 H); 5.08-4.98 (m, 8 H); 4.44 (p, J- 5.0 Hz, 1 H); 4.36 (p, J= 6.1 Hz5 1 H); 4.14 (dd, J= 7.2, 5.0 Hz, 4 H); 1.18 (d, J- 6.1 Hz5 6 H).
Step H: Tetrabenzyl 2-(4-hydroxy-3-isopropoxyphenoxy')propane-l,3-diylbis(phosphate)
0.1% (w/v) NaOH in water/MeOH (1 :9) (1737 μL, 0.043 mmol) was added to a stirred solution of 4-[2-{[bis(benzyloxy)ρhosphoryl]oxy}-l- ({[bis(benzyloxy)phosphoryl]oxy}methyl)ethoxy]-2-isopropoxyphenyl benzoate (125.5 mg, 0.145 mmol) in MeOH (4.83 mL) at 25 0C. Another 3 x 0.3 eq 0.1% (w/v) NaOH in water/MeOH were added. After 24 h, the reaction mixture was concentrated in vacuo to remove most of the MeOH. The aqueous mixture was diluted with water (10 mL) and IN HCl (5 mL) and extracted with EtOAc (3 x 15 mL). The combined extracts were dried (Na2SO4) and concentrated in vacuo to give the crude product. This was purified by flash chromatography (Biotage Horizon, 25M, Si, -20 mL/min, 100% hexanes for 144 mL, gradient to 100% EtOAc over 2394 mL) to afford tetrabenzyl 2-(4-hydroxy-3-isopropoxyphenoxy)propane-l,3- diylbis(phosphate), as a colorless oil. R/ = 0.19 (50% EtOAc in hexanes). LCMS calc. = 763.24; found = 763.07 (M+H)+. 1H NMR (500 MHz, CHCl3): δ 7.31 (m, 20 H); 6.77 (d, J= 8.7 Hz, 1 H); 6.54 (d, J= 2.7 Hz5 1 H); 6.37 (dd, J= 8.7, 2.7 Hz, 1 H); 5.67 (s, 1 H); 5.07-4.98 (m, 8 H); 4.41 (p; J= 6.1 Hz, I H); 4.34 (p, J= 5.00 Hz, 1 H); 4.14 (t, J- 6.1 Hz, 4 H); 1.28 (d, J= 6.1 Hz, 6 H).
EXAMPLE 1
Figure imgf000027_0001
(lJR,2y)-l-[3,5-Bis(trifluoromethvπphenyll-l-(j'('2,6-dimethoxyphenoxy)carbonyl1oxyl-N-{f4'- fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethγl)biphenyl-2-vl]methyl}propan-2-aminium chloride
Steυ A: (lJ?,2y>-143.5-Bis(triiluoromethyl)phenyll-2-fferr-butoxycarbonvl){r4'-fluoro-5'- isopropyl-2'-methoxy-4-(trifluρromethyl)biphenyl-2-yl]methyUamino)ρropyl 2,6- dimethoxyphenyl carbonate
Pyridine (0.035 mL, 0.437 mmol) was added dropwise to a stirred solution of 2,6- dimethoxyphenol (67.4 mg, 0.437 mmol) and triphosgene (47.4 mg, 0.160 mmol) in dry CH2Cl2 (4 mL) at 0 0C under N2. The reaction was stirred at 25 0C for 1.5 h. A solution of tert-butyl
{(15',2i?)-2-[3>5-bis(trifluoromethyl)phenyl]-2-hydroxy-l-methy!ethyi} {[4'-fiuoro-5'-isopropyl- 2'-methoxy-4-(trifluoromelhyl)biphenyl-2-yl]methyl} carbamate (INTERMEDIATE 7, 155.6 mg, 0.219 mmol) in dry CH2Cl2 (2 mL) was added via cannula followed by dropwise addition of pyridine (0.040 mL, 0.492 mmol). The reaction was stirred at 25 0C for 3 h. The reaction was diluted with water (15 mL) and extracted with EtOAc (3 x 20 mL). The combined extracts were dried (MgSO4) and concentrated in vacuo to give the crude product. This was purified by flash chromatography (Biotage Horizon, 25M, Si, -20 niL/min, 100% hexanes for 144 mL, gradient to 20% EtOAc in hexanes over 2394 mL) to give (liϊ,25)-l-[3,5-bis(trifluoromethyl)phenyl]-2- ((tert-butoxycarbonyl){[4t-fluoro-5t-isopropyl-2!-methoxy-4-(trifluoromethyl)biphenyI-2- yl]methyl}amino)propyl 2,6-dimethoxyphenyl carbonate, as a colorless oil. R/ = 0.51 (20% EtOAc/hexanes). LCMS calc. = 914.3; found - 914.1 (M+H)+.
Step B : ( 1 R,2S)- l,-[3 ,5-Bis(trifluoromethyl)phenyl] - 1 - { [(2,6-dimethoxyphenoxy)carbonyl] oxy } - N- { r4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]methy3 } ρroρan-2- arninium chloride A solution of (lΛ,2S)-l-[3,5-bis(trifluoromethyl)phenyl3-2-((/ert- butoxycarbonyl){[4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifiuoromethyl)biphenyl-2- yl]methyl}amino)propyl 2,6-dimethoxyphenyl carbonate (125.7 mg, 0.141 mmol) in HCl saturated EtOAc (4 mL) was stirred at 25 0C for 5 h. The reaction mixture was concentrated in vacuo to afford (liff25)-l-[3,5-bis(trifluoromethyl)phenyl]-l-{[(2,6- dimethoxyphenoxy)carbonyl]oxy} -JV- { [4'-fluoro-5'-isopropyI-2'-methoxy-4-
(trifluoromethyl)biρhenyl-2-yl]methyl}propan-2-aminium chloride, as a colorless oil/glass. LCMS calc. = 792.2; found = 792.2 (M+H)+.
The following carbonates (Table 2) were synthesized using methods analogous to those described in EXAMPLE 1 from commercially available choloroformates, chlorothioformates, phenols and alcohols. The conditions employed in EXAMPLE 1 , Step B were also successful in removing any tert-butyl carbamate or ester groups present in the alcohol or phenol residue of the carbamate such as that present in INTERMED ATE 5.
Figure imgf000028_0001
Figure imgf000028_0002
Figure imgf000029_0001
Figure imgf000030_0001
Figure imgf000031_0001
EXAMPLE 32
Figure imgf000031_0002
flJ?,21$f)-l-p,S-Bisftrifluoromelhvnphenyl"j-Λr-{[4'-fluoro-5l-isoρropvl-2'-methoxv-4- (trifluoromethyl)biphenyl-2-yl1methvU-l-r((2-methoxy-4-[2- (ρhosphonooxy)ethyl]phenoxy)carbonyl)oxy]ρropan-2-aminiuniιchloride Step A: 4-(2-Hydroxyethyl)-2-rnethoxyphenyl acetate A solution of l-acetyl-lH-l,2,3-triazolo[4,5-b]pyridine (0.964 g, 5.95 mmol) in dry THF (24 niL) was added to a solution of homovanillyl alcohol (1,00 g, 5.95 mmol) in IN aq. NaOH (5.95 mL, 5.95 mmol) at 25 0C. The reaction was stirred at 25 0C for 60 min. The reaction was diluted with IN HCl (40 mL) and extracted with Et2O (3 x 50 mL). The combined extracts were dried (MgSO4) and concentrated in vacuo to give the crude product. This was purified by flash chromatography (Biotage Horizon, 4OM, Si, -30 mL/min, 100% hexanes for 144 mL, gradient to 50% EtOAc in hexanes over 360 mL, gradient to 100% EtOAc over 1944 mL) to afford 4-(2-hydroxyelhyl)-2-rnethoxyphenyl acetate, as a colorless oil. R/ = 0.71 (EtOAc). LCMS calc. = 233.1 ; found = 233.1 (M+Na)+. 1H NMR (500 MHz, CDCl3): δ 6.95 (d, J= 8.0 Hz, I H); 6.83 (d, J= 1.8 Hz, 1 H); 6.79 (dd, J= 1.8, 8.0 Hz, 1 H); 3.88 (t, J= 6.6 Hz, 2 H), 3.84 (s, 3 H); 2.82 (t, J= 6.5 Hz, 2 H); 2.30 (s, 3 H); 1.76 (s, 1 H).
Step B: 2-Methoxy-4-(2-{[(4-methylphenyl)sulfonyl1oxvlethyl)p,henyl acetate
/7-ToluenesuIfonyl chloride (2.14 mL, 11.2 mmol) was added to a stirred solution of 4-(2-hydroxyethyl)-2-methoxyphenyl acetate (1.18 g, 5.61 mmol) in dry pyridine (20 mL) at 0 0C under N2. The reaction was stored at 4 0C for 3 days. The reaction was diluted with water (50 mL) and extracted with EtOAc (3 x 50 mL). The combined extracts were dried (MgSO4) and concentrated in vacuo to afford 2-methoxy-4-(2-{[(4-methylphenyl)sulfonyl]oxy}ethyl)phenyl acetate, as an oil. Product was a 6:4 mixture of desired product and starting material but carried forward regardless. LCMS calc. - 387.1; found = 386.8 (M+Na)÷.
Step C: 4-f2-Iodoethyl)-2-methoxyphenyl acetate
A 6:4 mixture of 2-methoxy-4-(2-{[(4-methylphenyl)sulfonyl]oxy}ethyl)phenyl acetate and 4-(2-hydroxyethyl)-2-methoxyphenyl acetate (1.57 g, 4.31 mmol) and sodium iodide (0.706 mL, 17.2 mmol) in dry acetone (28 mL) was stirred at room temperature overnight with protection from light. The acetone was removed in vacuo and the residue was triturated with toluene and filtered through a plug of Celite to remove insoluble inorganic material. The filtrate was concentrated in vacuo to afford the crude product. This was purified by flash chromatography (Biotage Horizon, 4OM, Si, ~30 mL/min, 100% hexanes for 360 mL, gradient to 50% EtOAc in hexanes over 4536 mL) to give 4-(2-iodoethyl)-2-methoxyphenyl acetate. R/ = 0.58 (20% EtOAc/hexanes). LCMS calc. = 321.0; found = 320.7 (M+H)+.
Step D: 4-(2-{[Bis(benzvloxv)phosphoryI1oxy}ethyl)-2-methoxyphenyl acetate Silver dibenzylphosphate (0.950 g, 2.47 mraol) was added to a solution of 4-(2- iodoethyl)-2-methoxyphenyl acetate (0.79 g, 2.47 mmol) in dry toluene (20 mL) and the mixture was heated at reflux overnight. The precipitated formed was removed by filtration through a plug of Celite and washed through with toluene. The filtrate was concentrated in vacuo to give the crude product. This was purified by flash chromatography (Biotage Horizon, 4OM, Si, -30 mL/min, 100% hexanes for 360 mL, gradient to 50% EtOAc in hexanes over 4536 mL) to afford 4-(2-{[bis(benzyloxy)phosphoryl]oxy}ethyl)-2-methoxyphenyl acetate, as a colorless oil. R/ = 0.31 (%0% EtOAc/hexanes). LCMS calc. = 471.2; found = 470.9 (M+Na)+. 1H NMR (600 MHz, CDCl3): δ 7.37-7.31 (m, 10 H); 6.92 (d, J= 8.0 Hz, 1 H); 6.76 (d, J = 1.8 Hz, 1 H); 6.72 (dd, J= 1.9, 8.0 Hz, I H); 5.01-4.95 (m, 4 H); 4.17 (q, J = 7.2 Hz, 2 H); 3.76 (s, 3 H); 2.89 (t, J= 7.0 Hz5 2 H); 2.30 (s, 3 H).
Step E: Dibenzyl 2-(4-hydroxy-3-methoxyphenyl)ethyl phosphate
K2CO3 (126 mg, 0.910 mmol) was added to a stirred solution of 4-(2- {[bis(benzyloxy)phosphoryl]oxy}ethyl)-2-methoxyphenyl acetate (214 mg, 0.455 mmol) in MeOH (30 mL) at 25 0C. The reaction was stirred at 25 0C for 1 h. The reaction mixture was concentrated in vacuo and the resulting residue was partitioned between water (20 mL) and EtOAc (20 mL). The aqueous layer was separated and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried (MgSO4) and concentrated in vacuo to afford dibenzyl 2- (4-hydroxy-3-methoxyphenyl)ethyl phosphate, as an oil. LCMS calc. = 429.2; found = 429.1 (M+Na)+.
Step F: 4-f2-{[Bis(benzyloxy)phosphoryl]oxyiethyl)-2-methoxyphenyl (IRjLS)-I-B 5- bis(trifluoromethyl)phenyl] -2-(f ferf -butoxycarbonyl) { [4'-fluoro-5 '-isopropyl-2'-methoxy-4- (trifluoromethyl)biphenyl-2-yl)methyl } amino)propy 1 carbonate
Pyridine (0.037 mL, 0.455 mmol) was added dropwise to a stirred solution of dibenzyl 2-(4-hydroxy-3-methoxyphenyl)ethyl phosphate (195 mg, 0.455 mmol) and triphosgene (49.3 mg, 0.166 mmol) in dry CH2Cl2 (4 mL) at 0 0C under N2. The reaction was stirred at 25 0C for 1.5 h. A solution of tert-buXy\ {(lJS1 !2i?)-2-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxy-l- methylethyl} {[4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biρhenyl-2~ yl]methyl} carbamate (INTERMEDIATE 7, 162.0 mg, 0.228 mmol) in dry CH2Cl2 (2 mL) was added via cannula followed by dropwise addition of pyridine (0.041 mL, 0.512 mmol). The reaction was stirred at 25 0C for 3 h. The reaction was diluted with water (15 mL) and extracted with EtOAc (3 x 20 mL). The combined extracts were dried (MgSO4) and concentrated in vacuo to give the crude product. This was purified by flash chromatography (Biotage Horizon, 25M, Si, -20 mL/min, 100% hexanes for 144 mL, gradient to 50% EtOAc in hexanes over 2394 mL) to give 4-(2-{[bis(benzyloxy)phosphoryl]oxy}ethyI)-2-methoxyphenyl ( lRt2S)-l -[3,5- bis(trifluoromethyl)phenyl]-2-((fer?-butoxycarbonyl){[4'-fluoro-5'-isopropyl-2'-raethoxy-4- (trifluoromethyl)biphenyl-2-yl] methyl }amino)propyl carbonate, as a colorless oil. R/ = 0.63 (50% EtOAc/hexanes). LCMS calc. = 1166.4; found - 1 166.4 (M+H)+.
Step G: fli?,2^-l-[3,5-Bis(trifluoromethvl)phenyll-2-f(/e^-butoxycarbonylHr4'-fluoro-5'- isoρropyl-2'-methoxy:4-(trifluoromethyl)biphenyl-2-yl]methyl}amino)propyl 2-methoxy-4-[2- (phosρhonρoxy)ethyl] phenyl carbonate
A suspension of 10% palladium on carbon (7.9 rag, 0.074 mmol) in a solution of 4-(2- { [bis(benzyloxy)phosphoryl] oxy } ethyl)-2-methoxyphenyl ( 1 R,2S)- 1 - [3 ,5 - bis(trifluorornethyl)phenyl]-2-((/er/-butoxycarbonyl){ [4'-fluoro-5'-isopropyl-2'-methoxy-4-
(trifluoromethyl)biρhenyl-2-yl] methyl }amino)propyl carbonate (86.2 mg, 0.074 mmol) in ethanol (5.7 mL) was stirred under H2 (double balloon pressure) at 25 0C for 5 h. The reaction mixture was filtered through a plug of Celite and the filtrate was concentrated in vacuo to afford (17?,25)- l-[355-bis(trifluoromethyl)phenyl]-2-((tert-butoxycarbonyl){[4'-fluoro-5'-isopropyl-2'-methoxy- 4-(trifluoromethyl)biphenyl-2-yl]methyl}amino)propyl 2-methoxy-4-[2-
(phosphonooxy)ethyljphenyi carbonate. LCMS calc. - 1008.8; found = 1008.8 (M+Na)+.
Step H: (li?,2y)-l-l'3,5-Bis('trifluoromethyl)phenvil~N-{['4<-fluoro-5'-isopropyl-2'-methoxv-4- (trifluoromethyl)biphenyl-2-yl]methyU - 1 -f( {2-methoxy-4-f2- (phosphonooxy)ethγI]phenoxy}carbonyl)oxy]propan-2-aminium chloride
A solution of (lΛ,2S)-l-[3,5-bis(trifluoromethyl)phenyl]-2-((/er/- butoxycarbonyl){[4'-fluoro-5'-isoρropyl-2t-methoxy-4-(trifluoromethyi)biphenyl-2- yl]methyl}amino)propyl 2-methoxy-4-[2-(phosphonooxy)ethyl]phenyl carbonate (72.9 mg, 0.074 mmol) in HCl saturated EtOAc (2 mL) was stirred at 25 °C for 5 h. The reaction mixture was concentrated in vacuo to afford (lΛ}2iS)-l-[3,5-bis(trifluorornelhyl)phenyl]-7l/-{[4l-fluoro-5'- isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]methyl } - 1 -[( { 2-methoxy-4- [2- (phosphonooxy)ethyl]phenoxy}carbonyl)oxy]propan~2-aminium chloride, as a colorless oil/glass. LCMS calc. - 886.2; found - 886.0 (M+H)+.
The following carbonates (Table 3) were synthesized using methods analogous to those described in EXAMPLE 32 from commercially available alcohols or those whose syntheses are described above. TABLE 3
Figure imgf000035_0001
Figure imgf000035_0002
Figure imgf000036_0001
Figure imgf000037_0001
EXAMPLE 44
Figure imgf000037_0002
( 1 R, 2S)- 1 -f ( [4-f Amrnoniomethvi )-2~methoxyphenoxy] carbonyl }.oxy): 1 -.[ 3 , S- bis(trifluoromethyl)phenyU-Λf-{[4'-fluoro-5'-isopropγl-2'-methoxy-4-(trifluoromethyljbiphenyl-
2-yl } methyl } propan-2-ami ni um dichlor ide
Step A: teλt-Butyl(4-hydroxy-3-rnethoxybenzyl)carbamate
To a solution of 4-hydroxy-3-methoxybenzylamine (1.0 g, 5.27 mmol) in acetonitrile (30 mL) was added /erf-butyldicarbonate (1.27 g, 5.80 mmol) and di- isopropylethylamine (1.84 mL, 10.54 mmol). The reaction was stirred at room temperature for 16 h before being partitioned between EtOAc (60 mL) and water (30 mL). The aqueous phase was separated and re-extracted with EtOAc (3 x 25 mL) and the combined organic extracts were washed with brine (60 mL), dried over MgSO4, filtered and concentrated. Purification by flash chromatography (40% EtOAc/hexanes) gave /er/-Butyl(4-hydroxy-3-methoxybenzyl)carbamate. LCMS - 275.9 (M+l)+. Step B : f 1 R2S)- 1 - [3 ,5 -B is(trifluoromethyl)pheny 1] -2 -((f erfrbutoxycarbony Q { |"4 ' -fl uoro- 5 ' - isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yljmethyl}amino)propyI-4-{[re/'/- butoxycarbonyQamino] methyl } -2-methoxyphenyl carbonate
Pyridine (0.048 rnL, 0.587 mmol) was added dropwise to a stirred solution oϊtert- butyl(4-hydroxy-3-methoxybenzyl)carbamate (149 mg, 0.587 mmol) and triphosgene (64 mg, 0.214 mmol) in dry CH2Cl2 (4.0 mL) at 00C under N2. The reaction was stirred at 25 0C for 1.5 h. A solution of fert-butyl {(liS',2JΪ)-2-[3J5-bis(trifluoromethyl)phenyl]-2-hydroxy-l- methylethyl } { [4 ' -fluoro-5 ' -isopropyl-2 ' -methoxy-4-(trifluoromethyl)biphenyl-2- yl]methyl}carbamate (INTERMEDIATE 7, 209 mg, 0.294 mmol) in dry CH2Cl2 (2 mL) was added followed by dropwise addition of pyridine (0.053 mL, 0.587 mmol). The reaction was stirred at 25 0C for 3 h. The reaction was diluted with water (15 mL) and extracted with EtOAc
(3 x 20 mL). The combined extracts were dried (MgSO4) and concentrated in vacuo to give the crude product. This was purified by flash chromatography (0-20% gradient EtOAc/hexanes over 30 min) to give (l/t>25;-l-[3J5-bis(trifiuoromethyl)phenyl]-2-((førr-butoxycarbonyl){[4'-fiuoro- 5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyI-2-yl]methyl}amino)propyl-4-{[/er/- butoxycarbonyl)amino] methyl} -2-methoxyphenyl carbonate as a colorless oil. R/ = 0.51 (20% EtOAc/hexanes). LCMS calc. - 990.9; found = 991.3 (M+H)+.
Step C : ( 1 R2S)- 1 -( I [4-(Ammoniomethyl V2-methoxyphenoxy3carbonyi > oxy)- 1 - [3 ,5- bis(trifluoromethyl)pherryl } -N- { [4' -fluoro-5 ' -isopropyl-2' -methoxy-4-(trifluoromethyl)biphenyl- 2-yl I methyl I propan-2-aminium dichloride
A solution of ( \R,2S)-1 -[3 ,5-bis(trifluoromethyl)phenyl]-2-((tert- butoxycarbonyl) { [4'-fluoro-5 ' -isopropyl-2 '-methoxy-4-(trifiuoromethyI)biphenyl -2- yl]methyl}amino)propyl-4-{[ϊert-butoxycarbonyl)amino]methyl}-2-methoxyphenyl (50 mg, 0.050 mmol) in HCl saturated EtOAc (3 mL) was stirred at 25 0C for 3 h. The reaction mixture was concentrated in vacuo to afford ( \R,2S)- 1-({ [4-(ammoniomethyl)"2- methoxyphenoxy]carbonyl}oxy)-l-[3s5-bis(trifiuoromethyl)phenyl}-iV-{[4'-fluoro-5'-isopropyl- 2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl}methyl}proρan-2-aminium dichloride as a white solid. LCMS calc. - 790.7; found = 791.1 (M+H)+. EXAMPLE 45
Figure imgf000039_0001
('7j^.81yι-7-P■5-Bisftrifluo^omethvnphenyll-N-i^4'-fluoro-5'-isopropvl-2'-methoxv-4-
(trifluoromethyl)bipheny}-2-yl]methyl}-lJ-dihvdroxy-5-oxo-2,4,ι6-trioxa-l-phosphanonan-8- aminium-1 -oxide chloride
Step A: (lJff,2iSf)-l-j"3.5-Bisftrifluoromethyl)phenylV2-fferf-butoxvcarbonyl)(r4'-fluoro-5'- isopropyl-2'-methoxy-4-(trifluoromethyl)biphenγl-2-vl]methyl}amino)propyl chloromethyl carbonate
Chloromethyl chloroformate (0.027 mL, 0.30 mmol) was added dropwise to a stirred solution of rert-butyl {(15,2i?)-2-[3!5-bis(trifluoromethyl)phenyI]-2-hydroxy-l- methylethyl} { [4' -fluoro-5 ' -isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2- yl]methyl}carbamate (INTERMEDIATE 7, 209 mg, 0.294 mmol) (200 mg, 0.28 mmol) and proton sponge (60 mg, 0.28 mmol) in dry CH2Cl2 (5.0 mL) at 00C under N2. The reaction was stirred at 25 0C for 16 h. The reaction was diluted with water (30 mL) and extracted with EtOAc
(3 x 30 mL). The combined extracts were dried (MgSO4) and concentrated in vacuo to give the crude product. This was purified by flash chromatography (0-20% gradient EtOAc/hexanes over 30 min) to give (li?,21S)-l-[3,5-bis(trifluoromethyl)phenyl]-2-(fert-butoxycarbonyl){[4'-fluoro- 5 '-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]methyl } amino)ρropyl chloromethyl carbonate as a colorless oil. 1H NMR (500 MHz, CDCl3): δ 7.81-6.82 (m, 8 H); 7.08 (dd, J = 8.3 Hz, 8.7 Hz, 1 H); 5.68 (m,2 H); 4.19-4.16 (d, J= 16.7 Hz, 1 H); 4.77 (s, 3 H), 3.31-3.24 (m, I H); 1.76 (s, 3 H); 1.41 (s, 3 H); 1.22-1.18 (s, 9 H), 1.04 (d, J- 6.6 Hz, 3 H).
Step B : ([Bi sf benzylox y)ρho sphoryll oxy) methylf IR 2S)-I- j"3 ,5-bis(trifluoromethyl)phenvI 1 -2- førf-butoxycarbonyl) { f4'-fluoro-5 ?-ιisopropyl-2i-methoxy-4-(trifluoromethyl)biphenyl-2- y 1 ] methyl } ammo)propyl carbonate Silver dibenzylphosphate (22 mg, 0.056 mmol) was added to a solution of ( 1 R,2S)- 1 - [3 , 5 -bi s(trifluoromethyϊ)phenyl] -2-(terf-butoxycarbony 1) { [4 ' -fluoro-5 ' -isopropyl-2 ' - methoxy-4-(trifluoromethyl)biphenyl-2-yl]methyl}amino)propyl chloromethyl carbonate (45 mg, 0.056 mmol) in dry toluene (3 niL) and the mixture was heated at reflux for 16 h. The precipitate formed was removed by filtration through a plug of Celite and washed with toluene (3 x 15 mL). The filtrate was concentrated in vacuo to give the crude product. This was purified by flash chromatography (0-20% EtOAc/hexanes) to afford
{ [Ms(benzyloxy)phosphoryl ] oxy } methyl( 1 R,2S)- 1 - [3 , 5 -bis(lr ifluoromethy l)pheny 1] -2-(tert~ butoxycarbonyl) { [4 '-fluoro-5 '-isopropyl-2' -methoxy-4-(trifluoromethyl)biphenyl-2- yl]methyl}amino)propyl carbonate, as a colorless oil. LCMS caic. = 1045.89; found = 1068.2 (M+Na)+.
Step C: riJ?,21y)-l-[3,5-Bisαrifluoromethvnphenyl]-2-(fert-butoxycarbonyl){f4'-fluoro-5'- isopropyl-2 ' -methoxy-4-(trifluoromethyl)biphenyl~2-yl]methyl } amino)prppyl (phosphonooxy)methγl carbonate
A suspension of 10% palladium on carbon (4.0 mg) and
{ [ Ms(benzy loxy)phosphory 1] oxy } methyl ( 1 R,2S)- 1 - [3 ,5 -bis(tr ifluoromethy l)pheny l]-2-(/err~ butoxycarbonyl) {[4 '-fluoro-5 '-isopropyl-2 '-methoxy-4-(trifluoromethyl)biphenyl-2~ yl]methyl}amino)propyl carbonate (17 mg, 0.016 mmol) in ethyl acetate (2.0 mL) was stirred under H2 (double balloon pressure) at 25 0C for 16 h. The reaction mixture was filtered through a plug of Celite and the filtrate was concentrated in vacuo to afford (lJ?,2S)-l-[3,5- bis(trifluoromethyl)phenyl] -2-(tøt-butoxycarbonyl) { [4' -fluoro-5 ' -isopropyl-2 ' -methoxy-4- (trifluoromethyl)biphenyl-2-yl] methyl }amino)propyl (phosphonooxy)methyl carbonate. LCMS calc. = 865.2; found = 887.9 (M+Na)+.
Step D : (IRSS)-I- [3 ,5 -Bisf trifluoromethyDphenvl] -JV- f [4 ' -fluoro-5 ' -isopropyl-2 ' -methoxy-4- (trifluoromethyl)biphenyl-2-yl] methyl} - 1 , 1 -dihydroxy-S-oxo-^ A,6-trioxa- 1 -phosphanonan-8- aminium- 1 -oxide chloride
A solution of (li?,2S)-l-[3,5-bis(trifluoromethyl)phenyl]-2-(ferϊ- butoxycarbonyl) { [4 ' -fluoro-5 ' -isopropyl-2 ' -methoxy-4-(tr ifluoromethyl )biphenyl-2- yl]methyl}amino)propyl (phosphonooxy)methyl carbonate (9 mg, 0.010 mmol) in HCl saturated EtOAc (3 mL) was stirred at 25 0C for 3 h. The reaction mixture was concentrated in vacuo to afford (7i?,85)~7-[3,5-bis(trifluoromethyl)phenyl]~N-j;[4'-fluoro-5'-isopropyl-2'-methoxy-4- (trifluoromethyl)biphenyI-2-yl]methyl}-l ,l-dihydroxy-5-oxo-2,4,6-trioxa-l-ρhosphanonan-8- aminium-1 -oxide chloride, as a colorless oil/glass. LCMS calc. = 801.2; found = 803.4 (M+H)+. EXAMPLE 46
Figure imgf000041_0001
(l/?,2^-l-[3,5-Bis(trifluoromethyl)phenyl]4-{[(carboxyniethoxy)carbonyl]oxy}-JV-(r4'-fluoro- 5'-isopropyl-2'-melhoxy-4-(trifluoromethyl)biphenyl-2-yl]methyl}propan-2-aminium chloride. Step A: Benzyl (6R J)Sf)-643,5-bis(trifluoromethvl)phenvl]-8-{[4'-fluoro-5'-isopropyl-2>- methoxy-4-(trifluorρmethyl^biphenyl-2-yl]methyl} -7,1 1,11 -trimethyl-4,9-dioxo-3,5 J 0-trioxa-8- azadodecati- 1 -oate Pyridine (0.037 mL, 0.46 mmol) was added dropwise to a stirred solution of benzyl glycolate (76 mg, 0.46 mmol) and triphosgene (42 mg, 0.14 mmol) in dry CH2Cl2 (4.0 mL) at 0 0C under N2. The reaction was stirred at 25 0C for 1.5 h. A solution of tert-butyl
{(15',2i?)-2-[3,5-bis(trifiuoromethyl)phenyl]-2-hydroxy-l-methylethyl} {[41-fluoro-5'-isopropyl- 2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]methyl} carbamate (INTERMEDIATE 7, 100 mg, 0.294 mmol) in dry CH2Cl2 (2 mL) was added followed by dropwise addition of pyridine (0.017 mL, 0.21 mmol). The reaction was stirred at 25 0C for I h. The reaction was diluted with water
(15 mL) and extracted with EtOAc (3 x 20 mL). The combined extracts were dried (MgS O4) and concentrated in vacuo to give the crude product. This was purified by flash chromatography (0- 20% gradient EtOAc/hexanes over 30 min) to give benzyl(6J?;75)-6-[3,5- bis(trifiuoromethyl)phenyl]-8- { [4'-fluoro-5 '-isoproρyl-2-'-methoxy-4-(trifiuoromethyl-biphenyl- 2-yl]methyl}-7jl 1,1 l-trimethyl~4,9-dioxo-3,5510-trioxa~8-azadodecan~l-oate as a colorless oil. Rf = 0.51 (20% EtOAc/hexanes). LCMS calc. - 903.8; found = 926.0 (M+Na)+.
Step B: (6^J5)-6-[3<5-Bis(trifiuoromethvnphenyl]-8-{[4'-fluoro-5'-isopropyl-2'-methoxy-4- (trifluoromethyl)biphenyl-2-yl]methyl}-7, 11,11 -trirnehtyl-4,9-dioxo-3,5, 10-trioxa-8-azadodecan- 1 -oic acid
A suspension of 10% palladium on carbon (3.0 mg), benzyI(6J?,75)-6-[3,5- bis(trifluoromethyl)phenyl]-8-{[4'-fluoro-5'-isopropyl-2-'-methoxy-4-(trifiuoromethyl-biphenyI- 2-yl]methyl}-7,l l ,l l-trimethyl-4;9-dioxo-3,5!10-trioxa-8-a2;adodecan-l-oate (25 mg, 0.028 mmol) and 1 -methyl 1 ,4-cyclohexadiene (26 mg, 0,28 mmol) in ethanol (2.0 tnL) was stirred at 25 0C for 16 h. The reaction mixture was filtered through a plug of Celite and the filtrate was concentrated in vacuo to (6Λf71S)-6-[3,5-bis(trifluoromethyl)phenyl]-8-{[4'-fluoro-5'-isopropyl- 2' -methoxy~4-(trif!uoromethyl)biphenyl-2-yl] methyl } -7, 11 , 11 -trimehtyI-4,9-dioxo-3 ,5 , 10-trioxa- 8-azadodecan-l-oic acid. LCMS calc. - 813.7; found - 835.9 (M+Na)+.
Step C : (1 &2S)- 1 - F3 , 5 ~Bis(trifluoromethy Hphenyl] - 1 - { [f carboxymethoχy)carbony lioxy I -N- i f 4 ' - flupro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]rnethyl}propan-2-aminium chloride A solution of (δΛJSJ-β-IS^-bisCtrifluoromethy^phenyll-S-tμ'-fluoro-S1- isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]rnethyl}-7,l 1 ,11 -trimethyl-4,9~dioxo- 3,5,10-trioxa-8-azadodecan-l-oic acid (6 mg, 0.007 mmol) in HCl saturated EtOAc (2 mL) was stirred at 25 0C for 3 h. The reaction mixture was concentrated in vacuo to afford (1/?, 2S)-I- [3 ,5 -bis(trifiuoromethyl)phenyl] - 1 - { [(carboxymethoxy)carbonyl]oxy } -N- { [4 ' -fluoro-5 ' - isopropyl-2' -methoxy-4-(trifluoromethyl)biphenyl-2-yl3 methyl }propan-2-aminium chloride, as a colorless oil/glass. LCMS calc. = 713.6; found - 713.9 (M+H)+.
EXAMPLE 47
Figure imgf000042_0001
(8J;.9S)-8-r3,5-bis(trifluoromethvnphenylVJV-{[4'-fluoro-5'-isopropyl-2'-methoxy-4- (trifluoromethyl)biphenyl-2-yl]methvU-lJ-dihydroxy-6-oxo-4-[(phosphonooxy)methyl]-2,5^ trioxa-lλ5-phosphadecan-9-aminiuml -oxide chloride Step A: (IR2SD- 1 -[3 ,5-Bisdiifluoromeihvnphenyl1-2-(aerf-butoxycarbonvn ( f4'-fluoro-5'- isopropyl-2!-methoxy-4-(trifluoromethγl)biphenyl-2-yl]methyl} amino)propyl 2-phenyl- 1.3- dioxan-5-yl carbonate
Pyridine (0.035 mL, 0.437 mmol) was added dropwise to a stirred solution of 1,3- benzylidene glycerol (79 mg, 0.437 mmol) and triphosgene (47.4 mg, 0.160 mmol) in dry CH2Cl2 (4.00 mL) at 0 0C under N2. The reaction was stirred at 25 0C for 1.5 h. A solution of tert-buϊyl {(15,2i?)-2-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxy-l-methylethyl} {[4'-fluoro-5t- isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyI-2-yl]methyl}carbamate (155.6 mg, 0.219 mmol) in dry CH2Cl2 (2.00 mL) was added via cannula followed by dropwise addition of pyridine (0.040 mL, 0.492 mmol) . The reaction was stirred overnight at 25 0C. The reaction was diluted with water (15 mL) and extracted with EtOAc (3 x 20 mL). The combined extracts were dried (MgSO4) and concentrated in vacuo to give the crude product. This was purified by flash chromatography (Biotage Horizon, 25M, Si, ~20 mL/min, 100% hexanes for 144 mL, gradient to 20% EtOAc in hexanes over 2394 mL) to afford (U?,2S)-l-[3,5- bis(trifluoromethyl)phenyl]-2-((tert-butoxycarbonyl){ [4'-fluoro-5'-isopropyl-2'-methoxy-4- (trifluoromethyl)biphenyl-2-yl]methyl}amino)propyl 2-phenyl-l,3-dioxan-5-yl carbonate, as a colorless oil. R/ = 0.46 (20% EtOAc in hexanes). LCMS calc. - 940.29; found = 940.10 (M+Na)+.
Step B: (IR2S)- 1 -r3,5-Bisrtrifiuoromethyl)phenyll-2-((fe^-butoxycarbonyl) {f4!-fluoro-5'- isopropyl-2'-methoxγ-4-(trifluoromethyl)biphenyl-2-yl]methyl} amino)propyl 2-hydroxγ- 1 - (hydroxymethyDethyl carbonate
A suspension of 10% palladium on carbon (9.13 mg, 8.57 μmol) in a solution of (lJ?s25)-l-[3,5-bis(trifluoromethyl)phenyl]-2-((^rt-butoxycarbonyl){[4'-fluoro-5'-isopropyl-2t- methoxy-4-(trifluoromethyl)biphenyl-2-yl]methyl}amino)propyl 2-phenyl-l ,3-dioxan-5-yl carbonate (78.7 mg, 0.086 mmol) in EtOAc (6.60 mL) was stirred under H2 (double balloon pressure) at 25 0C for 15 h. The reaction mixture was filtered through a plug of Celite and the filtrate was concentrated in vacuo to afford (li?,25)-l-[3,5-bis(trifluoromelhyl)phenyl]-2-((rer?- butoxycarbonyl){[4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2- yl] methyl }amino)propyl 2-hydroxy-l-(hydroxymethyl)ethyl carbonate. LCMS calc. = 852.26; found = 852.10 (M+Na)+.
Step C : 2- { [Bis(benzyloxy)phosphoryl] oxy I - 1 -( { [bis(benzyloxy)phosphoryl] oxy } methyl)ethyl fli?,2^-l-f3,5-bisftrifluoromethvDphenyll-2-(('/erf-butoxvcarbonyl){[4'-fluoro-5'-isopropyl-2'- methoxy-4-f trifluoromethyl)biphenyl-2-yl] methyl } amino)propyl carbonate
Dibenzyl N,N-diisoρropylphosphoramidite (78 μL, 0.231 mmol) was added to a stirred solution of l//-tetrazole (0.45 M in CH3CN) (1027 μL, 0.462 mmol) and (lΛ,2S)-l-[3,5- bis(trifluoromethyl)phenyl]-2-((før/-butoxycarbonyl){[4l-fluo-O-51-isopropyl-2'-methoxy-4- (trifluoromethyl)biphenyl~2-yl]methyl}arnino)propyl 2-hydroxy-l-(hydroxymethyl)ethyl carbonate (63.9 mg, 0.077 mmol) in dry CH2Cl2 (2.85 mL) at 25 0C under N2. The reaction was stirred for 3 h at 25 0C. The reaction mixture was cooled to 0 0C and a solution of 3- chloroperoxybenzoic acid (69.0 μL, 0.308 mmol) in dry CH2Cl2 (1.43 mL) was added via cannula and the reaction was stirred at 0 0C. After 60 min the reaction was diluted with EtOAc (25 mL) and washed with successive portions of saturated Na2SO3 (20 mL) and saturated NaHCO3 (20 mL), dried (Na2SO4) and concentrated in vacuo to afford the crude product. This was purified by flash chromatography (Biotage Horizon, 25M, Si, -20 mL/min, 100% hexanes for 144 mL, gradient to 50% EtOAc in hexanes over 2394 mL, gradient to 100% EtOAc over 1269 mL) to afford 2-{[bis(benzyloxy)phosphoryl]oxy}-l-
( { [bis(benzyloxy)phosphoryl]oxy } methyl)ethyl ( 1 R,2S)- 1 - [3 ,5 -bis(trifluoromethyl)phenyl] -2- ((tert-butoxycarbonyl){[4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2- yl] methyl }amino)propyl carbonate, as a colorless oil. R/ - 0.61 (50% EtOAc in hexanes). LCMS calc. - 1350.40; found = 1350.47 (M+H)+.
Step D: (lj?,2y)-l-r3,5-Bis(trifluoromethvnphenvl1-2-((fe^-butoxvcarbonvl){[41-fluoro-5'- isopropyl-2'-methoxy-4-(trifluoromelhyl)biρhenyl-2-yl]me1Jhyl}amino)propyl 2-(phosphonooxy)- 1 -fYphosphonooxy)methyl ] ethyl carbonate A suspension of 10% palladium on carbon (6.0 mg, 5.65 μmol) in a solution of 2-
{ [bis(benzyloxy)phosρhoryl] oxy } - 1 -( { [bis(benzyloxy)phosphoryl] oxy } melhyl)ethyl ( 1 R,2S)- 1 - [355-bis(lrifluoromethyl)phenyl]-2-((rert-butoxycarbonyl){[4'-fluoro-5'-isopropyl-2'-methoxy-4- (trifluoromethyl)biphenyl-2-yl] methyl }amino)propyl carbonate in ethanol (4.35 mL) was stirred under H2 (double balloon pressure) at 25 °C for 3 h. The reaction mixture was filtered through a Teflon filter and the filtrate was concentrated in vacuo to afford (li?,2S)-l-[3,5- bis(trifluoromethyl)phenyl]-2-((tert-butoxycarbonyl){[4'-fluoro-5'-isoρroρyl-2i-methoxy-4- (trifluoromethyl)biphenyl-2-yl] methyl } amino)proρyl 2-(ρhosρhonooxy)- 1 - [(phosphonooxy)methyl]ethyl carbonate. LCMS calc. = 1012.19; found = 1012.20 (M+Na)+.
Step E: (8 &95V 8-f3,5-Bisαrifluoromethyl)phenyl|-AM f4'-fluoro-5'-isopropyl-2'-methoxy-4- (trifluoromethyl)biphenyl-2-yl]methyU-l,l-dihydroxy-6-oxo-4-|'(ρhosphonooxy)methyl]-2,5,7- trioxa-1 λ5-phosρhadecan-9-aminiuml -oxide chloride
A solution of (lJ?,2S)-l-[3s5-bis(trifluoromethyl)phenyl]-2-((te?'t- butoxycarbonyl){[4'-fiuoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2- yl]methyl}amino)propyl 2-(phosphonooxy)-l-[(phosphonooxy)methyl]ethyl carbonate (46.7 mg, 0.047 mmol) in HCl saturated EtOAc (3 mL) was stirred at 25 0C for 1 h. The reaction mixture was concentrated in vacuo to afford (8if,95)-8-[3,5-bis(trifiuoromethyI)phenyl]-iV-{[4'-fluoro-5'- isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]methyl } - 1 , 1 -dihydroxy-6-oxo-4- [(ρhosρhonooxy)methyl]-2J5,7-trioxa-lλ5-phosphadecan-9-aminiuml-oxide chloride, as a colorless glass/solid. LCMS calc. - 890.16; found = 890.00 (M+H)+.
EXAMPLE 48
Cyclization Reactions
The kinetics of the cyclization reactions of the compounds described herein could be followed by the procedure illustrated below for the compound of EXAMPLE 35.
Figure imgf000045_0001
The sodium salt of EXAMPLE 35 (20 mg, 0.025 mmol) was dissolved (sonicated to ensure dissolution) in 100 mM sodium phosphate buffer in D2O (pH 7.52, 2.2 mL) and heated at 37 0C in an oil bath. 50 μL aliquots were removed periodically. An aliquot was taken at 3 minutes, then every 15 minutes until 135 minutes from the start, then every 30 minutes until 225 minutes from the start. Each aliquot was diluted with MeCN-d3 (150 μL), and a 1H NMR spectrum was acquired (128 scans at 25 0C, with acquisition starting 3 minutes after the aliquot was taken from the reaction). The tl/2 was determined by examining the spectra to find the point in time where the ratio of starting material (SM) and product was 1 :1, based on 2 independent resolved signals in the aromatic region. The t1/2 was found to be 75-90 min. Liquid chromatography - mass spectrometry (LCMS) of the reaction mixture showed the oxazolidinone III to be the main product. A small amount of SM remained along with a compound having a minor NMR peak that may be attributed to the corresponding carbamate. A small amount (ca. 1%) of the monoethyl ester byproduct was also present as a contaminant from the BOC deprotection step.
Table 4 below provides half-life data for some of the compounds described above. The methods for determining the half-lives were approximately the same as described above, with variations in procedure depending on such variables as solubility and reaction rates. The cyclizations using the compounds of EXAMPLES 37, 38, and 47 were carried out in a mixed solvent (D2O/l,4-dioxane-ds = 1 :3) rather than a single solvent (D2O).
TABLE 4
Example No Half Life of Cvclization at 37 0C pH of solution
35 75-90 minutes 7.52
36 135-150 minutes 7.52
37 ~4 hours 7.68
47 -150 minutes 7.68
38 9-10 hours 7.68
It can be seen from the half-life data that different structures have different half lives for cyclization. The half-life can thus be adjusted by a practitioner in the art by making structural changes in the Z group, thereby optimizing the rate of cyclization to maximize the amount of absorption and minimize the magnitude of the food effect.

Claims

WHAT IS CLAIMED IS:
1. A compound of formula I, or a pharmaceutically acceptable salt thereof:
Figure imgf000047_0001
I
wherein Rl is selected from H and Ci _4alkyls which is optionally substituted with 1-5 F groups;
Each R.2 is independently selected from the group consisting of halogen, -CN5 Ci-4alkyl, and -0Cl-4alkyl, wherein Cl-4alkyl and -OCi-4alkyl are optionally substituted with
1-5 halogens;
R3 is selected from the group consisting of H, halogen, Ci-4alkyL and -OC l _4alkyl, wherein C i -4alkyl and -OC i _4alkyl are optionally substituted with 1 -5 halogens;
R4 and R5 are each independently selected from the group consisting of halogen, Ci-4alkyl, and -0Ci-4alkyl, wherein Ci-4alkyl and -0Ci-4alkyl are optionally substituted with
1-5 halogens;
R6 is selected from H and C1-C5 alkyl optionally substituted with 1-5 halogens and optionally substituted with 1-2 phenyl groups, wherein phenyl is optionally substituted with 1-3 groups independently selected from halogen, C1-C3 alkyl, -OC1-C3 alkyl, CF3, and -OCF3; R7 is selected from H and Q-C3 alkyl optionally substituted with 1-3 F; X is selected from -OZ and -SZ5 wherein Z is selected from: (a) Cj-C5 alkyl which optionally includes an -O- atom between 2 adjacent carbon atoms, wherein Cj-C5 alkyl is optionally substituted with 1-5 halogens and is optionally substituted with 1-2 substituent groups independently selected from phenyl, -C(=O)OR6, -OP(=O)(OR7)2, and -P(=O)(OR7)2, wherein phenyl is optionally substituted with 1-3 groups independently selected from halogen, -C(=O)OR7, and Ci-C3alkyl optionally substituted with 1-3 halogens; and (b) phenyl, wherein phenyl is optionally substituted with 1-3 groups independently selected from halogen; Cs-Csalkyl; -OCi-Csalkyl; -C(=O)OR7; and C5- Cycycloalkyl optionally substituted with 1-2 groups independently selected from halogen, Ci- C3alkyl, -OCrC3alkyl, CF3, and -OCF3; wherein d-C5alkyl and -OCrC5alkyl are optionally substituted with 1-5 F and are optionally substituted with 1-2 groups independently selected from -C(K))OR7, -N(R7)3, -OP(K))(OR7)2, and -P(K))(OR7)2;
a and b are integers independently selected from 0-4; and 5 c is an integer from 0-2,
2. The compound of Claim 1, wherein
Z is selected from
10 (a) C1-C5 alkyl which optionally includes an -O- atom between 2 adjacent carbon atoms, wherein C1-C5 alkyl is optionally substituted with 1-3 F and is optionally substituted with 1-2 substituent groups independently selected from phenyl, -C(K))ORo, -OP(-O)(OR7)2, and -P(=O)(OR7)2, wherein phenyl is optionally substituted with 1-3 groups independently selected from halogen, Ci-C3alkyl, CF3, and -C(K))OR7; and
] 5 (b) Phenyl, wherein phenyl is optionally substituted with 1 -3 groups independently selected from halogen; Q-Csalkyl; CF3; -0Cj-C3alkyl; -OCF3; -C(K))OR7; and Cg-Cβcycloalkyl which is optionally substituted with 1-2 groups independently selected from halogen, CH3, and -OCH3; wherein Ci-Csalkyl and -OC] -C3alkyl are optionally substituted with 1-2 groups independently selected from -C(K))OR?, -N(R7)2, -OP(K))(OR^)2; and
20 -P(K))(OR7)2.
3. The compound of Claim 2, wherein
Rl is C 1-2 alkyl, optionally substituted with 1-3 F;
25 Each R2 is independently selected from -CN, C 1-3 alkyl, CF3, -OCH3,
-0CF3, and F;
R3 is selected from C 1-3 alkyl, -0Ci-3alkyl , and F, wherein Ci-3alkyl and 0Ci-3alkyl are optionally substituted with 1-5 F;
R4 and R5 are each independently selected from Ci~3alkyl, CF3, -OCH3, 30 -OCF3, and F;
R6 is selected from H and Ci-Csalkyl, wherein C] -O^alky I is optionally substituted with one phenyl group, said phenyl being optionally substituted with 1 -3 groups independently selected from halogen, CH3, CF3, -OCH3, and -OCF3;
R7 is selected from H and C1-C3 alkyl optionally substituted with 1-3 F; 35 a is l or 2; b is an integer from 1-3; and c is 0 or 1.
4. The compound of Claim 3, wherein
X is selected from -SCi-C2alkyl and -OZ; Z is selected from the group consisting of
(a) -(CH2CH2θ-)nCi-C3alkyl, wherein Ci-C3alkyl is optionally substituted with 1-2 substituent groups independently selected from phenyl, -C(=O)OR6, - OP(-O)(OR7)2; and -P("O)(OR7)2, wherein phenyl is optionally substituted with one group -C(=O)OR7; and (b) phenyl, which is optionally substituted with 1-3 substituents independently selected from C1-C4 alkyl, -0Cj-C3alkyl, -C(=O)OR7, and cyclohexyl, wherein C1-C4 alkyl and -OCi-C3alkyl are optionally substituted with 1-2 groups independently selected from -N(R7)2, -C(=O)OR7, and -OP(=O)(OR7)2; and n is an integer selected from 0 and 1.
5. The compound of Claim 4, wherein
Rl is Ci-2 alkyl;
R2 is CF3; R3 is selected from CH3, CF3 and F;
Each R4 is independently selected from Cj-3alkyl, -OCH3, and F;
R6 is selected from H, Ci-C2alkyl, and -CH2phenyl;
R7 is selected from H and Ci-C2alkyl; a is 2; b is 2 or 3; and c is O.
6. The compound of Claim 5, wherein
Rl is CH3; and b is 3.
7. The compound of Claim 1 having formula IV, or a pharmaceutically acceptable salt thereof:
Figure imgf000050_0001
8. The compound of Claim 7, wherein Z is selected from the group consisting of:
(a) Ci -C 5 alkyl which optionally includes an -O- atom between 2 adjacent carbon atoms, wherein Ci-Cs alkyl is optionally substituted with 1-3 F and is optionally substituted with 1-2 substituent groups independently selected from phenyl, -C(=O)OR6, -OP(=O)(OR7)2, and
-P(=O)(OR7)2, wherein phenyl is optionally substituted with 1-3 groups independently selected from halogen, Ci-C3alkyl, CFs, and -C(O)OR?; and
(b) Phenyl, wherein phenyl is optionally substituted with 1-3 groups independently selected from halogen; Ci-Csalkyl; CF3; -0Ci-C3aUcyl; -OCF3; -C(O)OR7, and Cs-C6cycloalkyl which is optionally substituted with 1-2 groups independently selected from halogen, CH3, and -OCH3; wherein Cj-Csalkyl and -0Ci-C3alkyl are optionally substituted with 1-2 groups independently selected from -C(O)OR?, -N(R7)2J -OP(=O)(OR7)2, and
Figure imgf000050_0002
9, The compound of Claim 8, wherein
X is selected from -SCi~C2a]kyl and -OZ;
Z is selected from the group consisting of
(a) -(CH2CH2θ-)nCi-C3alkyl5 wherein Ci-C3alkyl is optionally substituted with 1-2 substituent groups independently selected from phenyl, -C(O)ORo, -0P(O)(0R7)2, and -P(=OXOR7)2, wherein phenyl is optionally substituted with one group -C(=O)OR7; and
(b) phenyl, which is optionally substituted with 1-3 substituents independently selected from C1-C4 alkyl, -OCi-Csalkyl, -C(HD)OR?, and cyciohexyl, wherein Ci-C4alkyl and -0Ci-C3alkyϊ are optionally substituted with 1-2 groups independently selected from -N(R7)2, -C(=0)0R7, and -OP(=O)(OR7)2; n is an integer selected from O and 1 ; and R6 is selected from the group consisting of H and C]-C2aϊkyl which is optionally substituted with one phenyl group, said phenyl being optionally substituted with 1-3 groups independently selected from halogen, CH3, CF3, -OCH3, and -OCF3,
10. The compound of Claim 9, wherein
X is selected from -SCi-C2alkyl and -OZ;
Z is selected from the group consisting of:
(a) -(CH2CH2θ-)nCi-C3alkyl, wherein C]-C3alkyl is optionally substituted with 1-2 substituent groups independently selected from phenyl, -C(=O)OR6, -0P(O)(0R7)2, ^d
-P(-O)(OR7)2, wherein phenyl is optionally substituted with one group -C(=O)OR7; and
(b) phenyl, which is substituted with 1-3 substituents independently selected from C1-C4 alkyl, -OCi-C3alkyl, -C(O)OR?, and cyclohexyl, wherein Cj-C-jalkyl and -0Ci-C3alkyl are optionally substituted with 1-2 groups independently selected from -N(R7)2, -C(=0)0R7, and -0P(O)(0R7)2;
Rό is selected from H, Cj-C^alkyl, and -CH2phenyl; and
R7 is selected from H and C]-C2alkyl.
11 , The compound of Claim 10, wherein X is -OZ.
12, A pharmaceutical composition comprising the compound of Claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
13, The compound of Claim 10, or a pharmaceutically acceptable salt thereof, wherein the compound has a structure which is selected from the group consisting of the following structures:
Figure imgf000052_0001
14. The compound of Claim 10, or a pharmaceutically acceptable salt thereof, wherein the compound has a structure which is selected from the group consisting of the following structures:
Figure imgf000053_0001
Figure imgf000053_0002
Figure imgf000054_0001
Figure imgf000055_0001
Figure imgf000056_0001
15. A method of raising HDL-cholesterol in a patient in need of treatment, comprising the administration of the compound of Claim 1, or a pharmaceutically acceptable salt thereof to the patient.
16. A method of lowering LDL-cholesterol in a patient in need of treatment, comprising the administration of the compound of Claim 1, or a pharmaceutially acceptable salt thereof to the patient.
17. A method of treating hypercholesterolemia in a patient in need of treatment, comprising the administration of the compound of Claim 1, or a pharmaceutially acceptable salt thereof to the patient.
18. The use of the compound of Claim 1 in the manufacture of a medicament for the treatment of hypercholesterolemia in a patient in need of treatment.
PCT/US2009/057657 2008-10-01 2009-09-21 Prodrugs of oxazolidinone cetp inhibitors WO2010039474A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP09818237.1A EP2348859B1 (en) 2008-10-01 2009-09-21 Prodrugs of oxazolidinone cetp inhibitors
US13/121,972 US8354454B2 (en) 2008-10-01 2009-09-21 Prodrugs of oxazolidinone CETP inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19491508P 2008-10-01 2008-10-01
US61/194,915 2008-10-01

Publications (1)

Publication Number Publication Date
WO2010039474A1 true WO2010039474A1 (en) 2010-04-08

Family

ID=42073814

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/057657 WO2010039474A1 (en) 2008-10-01 2009-09-21 Prodrugs of oxazolidinone cetp inhibitors

Country Status (3)

Country Link
US (1) US8354454B2 (en)
EP (1) EP2348859B1 (en)
WO (1) WO2010039474A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012141487A3 (en) * 2011-04-12 2013-01-10 Chong Kun Dang Pharmaceutical Corp. Cycloalkenyl aryl derivatives for cetp inhibitor
EP2567958A1 (en) 2011-09-12 2013-03-13 Sanofi Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals
WO2013037388A1 (en) 2011-09-12 2013-03-21 Sanofi Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals
WO2013063217A1 (en) * 2011-10-28 2013-05-02 Merck Sharp & Dohme Corp. Fused bicyclic oxazolidinone cetp inhibitor
WO2014111953A1 (en) * 2013-01-17 2014-07-24 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for preparation of anacetrapib and intermediates thereof
US8912224B2 (en) 2011-09-12 2014-12-16 Sanofi Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals
US9440941B2 (en) 2013-03-08 2016-09-13 Sanofi Substituted chroman-6-yloxy-cycloalkanes and their use as pharmaceuticals
WO2018016743A1 (en) * 2016-07-19 2018-01-25 재단법인 대구경북첨단의료산업진흥재단 Oxazolidinone derivative compound as cetp inhibitor
CN110639018A (en) * 2019-11-14 2020-01-03 牡丹江医学院 Pharmaceutical composition for preventing and treating senile hypertension and application thereof
WO2022075645A1 (en) * 2020-10-08 2022-04-14 재단법인 대구경북첨단의료산업진흥재단 Aminoalcohol derivative as pcsk9 inhibitor, and pharmaceutical composition for preventing or treating hypercholesteremia, containing same

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6030147B2 (en) * 2011-11-30 2016-11-24 デウン ファーマシューティカル カンパニー リミテッド Pharmaceutical composition for preventing or treating hypertriglyceridemia or diseases associated with hypertriglyceridemia
EP2934519B1 (en) * 2012-12-20 2021-05-12 Merck Sharp & Dohme Corp. Therapeutic thiazolidinone compounds
US11439653B1 (en) 2021-03-30 2022-09-13 Epalex Corporation Fospropofol formulations
US11547714B2 (en) 2020-02-05 2023-01-10 Epalex Corporation Fospropofol salts, methods and compositions
US11478490B1 (en) 2021-03-30 2022-10-25 Epalex Corporation Fospropofol formulations
US11628178B2 (en) 2019-03-26 2023-04-18 Epalex Corporation Fospropofol methods and compositions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080119476A1 (en) * 2004-07-02 2008-05-22 Amjad Ali Cetp Inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1737811B1 (en) * 2004-04-13 2016-08-10 Merck Sharp & Dohme Corp. Cetp inhibitors
AU2006335108B2 (en) * 2005-12-30 2011-04-07 Merck Sharp & Dohme Corp. CETP inhibitors
US7915271B2 (en) * 2005-12-30 2011-03-29 Merck Sharp & Dohme Corp. 1,3-oxazolidin-2-one derivatives useful as CETP inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080119476A1 (en) * 2004-07-02 2008-05-22 Amjad Ali Cetp Inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GOMES ET AL.: "Cyclization-activated Prodrugs.", MOLECULES, vol. 12, 2007, pages 2484 - 2506, XP008095509 *
SAARI ET AL.: "Cyclization-activated prodrugs. Basic carbamates of 4-hydroxyanisole.", J. MED CHERN., vol. 33, 1990, pages 97 - 101, XP001120293 *

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2597266C2 (en) * 2011-04-12 2016-09-10 Чхон Кхун Дан Фармасьютикал Корп. Cycloalkenylarylic derivatives for inhibiting transport protein cholesterin esters
CN103502226A (en) * 2011-04-12 2014-01-08 株式会社钟根堂 Cycloalkenyl aryl derivatives for CETP inhibitor
JP2014510786A (en) * 2011-04-12 2014-05-01 チョンクンダン ファーマシューティカル コーポレーション Cycloalkenyl aryl derivatives as CETP inhibitors
US9371294B2 (en) 2011-04-12 2016-06-21 Chong Kun Dang Pharmaceutical Corp. Cycloalkenyl aryl derivatives for CETP inhibitor
WO2012141487A3 (en) * 2011-04-12 2013-01-10 Chong Kun Dang Pharmaceutical Corp. Cycloalkenyl aryl derivatives for cetp inhibitor
US8912224B2 (en) 2011-09-12 2014-12-16 Sanofi Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals
EP2567958A1 (en) 2011-09-12 2013-03-13 Sanofi Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals
WO2013037388A1 (en) 2011-09-12 2013-03-21 Sanofi Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals
WO2013037724A1 (en) 2011-09-12 2013-03-21 Sanofi Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals
US9346825B2 (en) 2011-10-28 2016-05-24 Merck Sharp & Dohme Corp. Fused bicyclic oxazolidinone CETP inhibitor
KR101686308B1 (en) 2011-10-28 2016-12-13 머크 샤프 앤드 돔 코포레이션 Fused bicyclic oxazolidinone cetp inhibitor
CN103958524A (en) * 2011-10-28 2014-07-30 默沙东公司 Fused bicyclic oxazolidinone CETP inhibitor
KR20140094571A (en) * 2011-10-28 2014-07-30 머크 샤프 앤드 돔 코포레이션 Fused bicyclic oxazolidinone cetp inhibitor
US8871738B2 (en) 2011-10-28 2014-10-28 Merck Sharp & Dohme Corp. Fused bicyclic oxazolidinone CETP inhibitor
WO2013063217A1 (en) * 2011-10-28 2013-05-02 Merck Sharp & Dohme Corp. Fused bicyclic oxazolidinone cetp inhibitor
EA026123B1 (en) * 2011-10-28 2017-03-31 Мерк Шарп И Доум Корп. Fused bicyclic oxazolidinone as cetp inhibitor
WO2014111953A1 (en) * 2013-01-17 2014-07-24 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for preparation of anacetrapib and intermediates thereof
US9440941B2 (en) 2013-03-08 2016-09-13 Sanofi Substituted chroman-6-yloxy-cycloalkanes and their use as pharmaceuticals
WO2018016743A1 (en) * 2016-07-19 2018-01-25 재단법인 대구경북첨단의료산업진흥재단 Oxazolidinone derivative compound as cetp inhibitor
CN110639018A (en) * 2019-11-14 2020-01-03 牡丹江医学院 Pharmaceutical composition for preventing and treating senile hypertension and application thereof
CN110639018B (en) * 2019-11-14 2020-06-26 牡丹江医学院 Pharmaceutical composition for preventing and treating senile hypertension and application thereof
WO2022075645A1 (en) * 2020-10-08 2022-04-14 재단법인 대구경북첨단의료산업진흥재단 Aminoalcohol derivative as pcsk9 inhibitor, and pharmaceutical composition for preventing or treating hypercholesteremia, containing same
KR20220047168A (en) * 2020-10-08 2022-04-15 재단법인 대구경북첨단의료산업진흥재단 Aminoalcohol derivatives as PCSK9 inhibitor and pharmaceutical composition comprising the same for preventing or treating hypercholesterolemia
KR102651062B1 (en) 2020-10-08 2024-03-25 재단법인 대구경북첨단의료산업진흥재단 Aminoalcohol derivatives as PCSK9 inhibitor and pharmaceutical composition comprising the same for preventing or treating hypercholesterolemia

Also Published As

Publication number Publication date
EP2348859B1 (en) 2013-12-04
EP2348859A4 (en) 2012-03-21
US8354454B2 (en) 2013-01-15
EP2348859A1 (en) 2011-08-03
US20110218177A1 (en) 2011-09-08

Similar Documents

Publication Publication Date Title
WO2010039474A1 (en) Prodrugs of oxazolidinone cetp inhibitors
AU2017361251B2 (en) MAGL inhibitors
TWI304066B (en) Indole compounds
WO2010128401A9 (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
KR102265409B1 (en) Methods of treatment using lipid compounds
JPWO2002066464A1 (en) β-lactam compound, method for producing the same, and serum cholesterol lowering agent containing the same
UA82835C2 (en) ?-aryl-?-oxysubstituted propionuc acid derivatives and pharmaceutical composition based thereon
KR20010071962A (en) Medicine nitrate salts
JP6200603B2 (en) Β-substituted β-amino acids and analogs as chemotherapeutic agents
EP0068968B1 (en) Medicines containing as active ingredients compounds of the arylbenzenesulfonamide-type, and processes for their preparation
KR20220054626A (en) Pyrazole Compounds, Formulations Thereof, and Methods of Using the Compounds and/or Formulations
WO1996004234A1 (en) Aryloxy andarycthio propanolamine derivatives useful as b3-adrenoreceptor agonists and antagons of the b1 and b2 adrenoreceptors and pharmaceutical composition thereof
WO2005023204A2 (en) Aromatic prodrugs of propofol, compositions and uses thereof
NO970372L (en) Aroyloxy and aroylthiopropanolamine derivatives useful as &lt;beta&gt; -3-adrenoreceptor agonists and antagonists for &lt;beta&gt; -1 and &lt;beta&gt; -2-adrenoreceptors and pharmaceutical mixtures thereof
JP2869572B2 (en) Method for producing phosphatidylcholine derivative
EP0787135A1 (en) Water-soluble epipodophyllotoxin derivatives, preparation method therefor, and use thereof as a drug and for treating cancer
US7777071B2 (en) Production of carnitine conjugate intermediates
JP3577079B2 (en) Optically active 2-nitroimidazole derivative
JPH0733791A (en) New phospholipid derivative, production thereof, purification thereof, eradication of tumor, disease caused by protista and disease caused by eumycetes, medicine for treatment of autoimmune disease, skin disease, injure of marrow and viral disease and production of said medicine
JPH0124793B2 (en)
CN112824426B (en) Allopregnanolone phosphonamide derivative, preparation method and medical application thereof
US4820837A (en) 1-hydroxy-oxo-5H-pyrido(3,2-a)phenoxazine-3-carboxylic acid esters
RU2780118C2 (en) Iminourea derivatives
RU2656614C2 (en) Derivatives of oxalic acid, their use as chemosensitizers in combined anti-tumor therapy with cytostastics in the treatment of leukemia and drug-resistant leukemia, a method for production derivatives of oxalic acid
CN112513056A (en) Preparation method of trimethyl ammonium ethyl phosphono diethyl iodide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09818237

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 13121972

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009818237

Country of ref document: EP